0000021665 12/31 2020 Q3 false 0000021665 2020-01-01 2020-09-30 0000021665 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000021665 cl:A0.000Notesdue2021Member 2020-01-01 2020-09-30 0000021665 cl:A0.500NotesDue2026Member 2020-01-01 2020-09-30 0000021665 cl:A1.375NotesDue2034Member 2020-01-01 2020-09-30 0000021665 cl:A0.875Notesdue2039Member 2020-01-01 2020-09-30 xbrli:shares 0000021665 2020-09-30 iso4217:USD 0000021665 2020-07-01 2020-09-30 0000021665 2019-07-01 2019-09-30 0000021665 2019-01-01 2019-09-30 iso4217:USD xbrli:shares 0000021665 2019-12-31 0000021665 2018-12-31 0000021665 2019-09-30 0000021665 us-gaap:CommonStockMember 2020-06-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000021665 cl:UnearnedCompensationMember 2020-06-30 0000021665 us-gaap:TreasuryStockMember 2020-06-30 0000021665 us-gaap:RetainedEarningsMember 2020-06-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000021665 us-gaap:NoncontrollingInterestMember 2020-06-30 0000021665 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000021665 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000021665 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000021665 us-gaap:CommonStockMember 2020-09-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000021665 cl:UnearnedCompensationMember 2020-09-30 0000021665 us-gaap:TreasuryStockMember 2020-09-30 0000021665 us-gaap:RetainedEarningsMember 2020-09-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000021665 us-gaap:NoncontrollingInterestMember 2020-09-30 0000021665 us-gaap:CommonStockMember 2019-06-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000021665 cl:UnearnedCompensationMember 2019-06-30 0000021665 us-gaap:TreasuryStockMember 2019-06-30 0000021665 us-gaap:RetainedEarningsMember 2019-06-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000021665 us-gaap:NoncontrollingInterestMember 2019-06-30 0000021665 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000021665 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000021665 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000021665 cl:UnearnedCompensationMember 2019-07-01 2019-09-30 0000021665 us-gaap:CommonStockMember 2019-09-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000021665 cl:UnearnedCompensationMember 2019-09-30 0000021665 us-gaap:TreasuryStockMember 2019-09-30 0000021665 us-gaap:RetainedEarningsMember 2019-09-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000021665 us-gaap:NoncontrollingInterestMember 2019-09-30 0000021665 2020-06-30 0000021665 2019-06-30 0000021665 us-gaap:CommonStockMember 2019-12-31 0000021665 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000021665 cl:UnearnedCompensationMember 2019-12-31 0000021665 us-gaap:TreasuryStockMember 2019-12-31 0000021665 us-gaap:RetainedEarningsMember 2019-12-31 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000021665 us-gaap:NoncontrollingInterestMember 2019-12-31 0000021665 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000021665 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000021665 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000021665 cl:UnearnedCompensationMember 2020-01-01 2020-09-30 0000021665 us-gaap:CommonStockMember 2018-12-31 0000021665 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000021665 cl:UnearnedCompensationMember 2018-12-31 0000021665 us-gaap:TreasuryStockMember 2018-12-31 0000021665 us-gaap:RetainedEarningsMember 2018-12-31 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000021665 us-gaap:NoncontrollingInterestMember 2018-12-31 0000021665 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000021665 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0000021665 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000021665 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000021665 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0000021665 cl:UnearnedCompensationMember 2019-01-01 2019-09-30 cl:Dividend 0000021665 2019-01-01 2019-03-31 0000021665 2020-01-01 2020-03-31 0000021665 cl:HelloProductLLCMember 2020-01-31 2020-01-31 0000021665 cl:HelloProductLLCMember 2020-01-31 0000021665 us-gaap:TrademarksMember cl:HelloProductLLCMember 2020-01-31 0000021665 us-gaap:TrademarksMember cl:HelloProductLLCMember 2020-01-31 2020-01-31 0000021665 us-gaap:CustomerRelationshipsMember cl:HelloProductLLCMember 2020-01-31 0000021665 us-gaap:CustomerRelationshipsMember cl:HelloProductLLCMember 2020-01-31 2020-01-31 0000021665 srt:NorthAmericaMember cl:HelloProductLLCMember 2020-01-31 iso4217:EUR 0000021665 cl:LaboratoiresFilorgaCosmtiquesMember 2019-09-19 2019-09-19 0000021665 cl:LaboratoiresFilorgaCosmtiquesMember 2019-09-19 0000021665 us-gaap:TrademarksMember cl:LaboratoiresFilorgaCosmtiquesMember 2019-09-19 0000021665 us-gaap:CustomerRelationshipsMember cl:LaboratoiresFilorgaCosmtiquesMember 2019-09-19 0000021665 us-gaap:CustomerRelationshipsMember cl:LaboratoiresFilorgaCosmtiquesMember 2019-09-19 2019-09-19 0000021665 srt:EuropeMember cl:LaboratoiresFilorgaCosmtiquesMember 2019-09-19 0000021665 cl:LaboratoiresFilorgaCosmtiquesMember 2020-07-01 2020-09-30 xbrli:pure 0000021665 cl:NigeriaJointVentureMember 2019-08-15 0000021665 cl:NigeriaJointVentureMember 2019-08-15 2019-08-15 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2020-07-01 2020-09-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000021665 cl:OtherIncomeExpenseNetMember cl:GlobalGrowthandEfficiencyProgramMember 2020-07-01 2020-09-30 cl:case 0000021665 cl:GrossProfitMember cl:GlobalGrowthandEfficiencyProgramMember 2019-07-01 2019-09-30 0000021665 cl:GrossProfitMember cl:GlobalGrowthandEfficiencyProgramMember 2019-01-01 2019-09-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000021665 cl:OtherIncomeExpenseNetMember cl:GlobalGrowthandEfficiencyProgramMember 2019-07-01 2019-09-30 0000021665 cl:OtherIncomeExpenseNetMember cl:GlobalGrowthandEfficiencyProgramMember 2019-01-01 2019-09-30 0000021665 cl:NonServiceRelatedPostretirementCostsMember cl:GlobalGrowthandEfficiencyProgramMember 2019-07-01 2019-09-30 0000021665 cl:NonServiceRelatedPostretirementCostsMember cl:GlobalGrowthandEfficiencyProgramMember 2019-01-01 2019-09-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2019-07-01 2019-09-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2019-01-01 2019-09-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2020-06-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2020-09-30 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2019-12-31 0000021665 cl:GlobalGrowthandEfficiencyProgramMember 2020-01-01 2020-09-30 0000021665 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000021665 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0000021665 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000021665 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2019-09-30 0000021665 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000021665 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000021665 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000021665 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000021665 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000021665 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000021665 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000021665 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000021665 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000021665 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000021665 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000021665 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000021665 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000021665 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000021665 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000021665 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000021665 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-09-30 cl:country_and_territory 0000021665 srt:MinimumMember 2020-09-30 0000021665 srt:MaximumMember 2020-09-30 0000021665 2005-12-31 0000021665 2017-07-31 0000021665 2019-04-30 0000021665 2019-04-01 2019-06-30 cl:segment 0000021665 srt:NorthAmericaMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:NorthAmericaMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:NorthAmericaMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:NorthAmericaMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 srt:LatinAmericaMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:LatinAmericaMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:LatinAmericaMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:LatinAmericaMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 srt:EuropeMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:EuropeMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:EuropeMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:EuropeMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 srt:AsiaPacificMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:AsiaPacificMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:AsiaPacificMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:AsiaPacificMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2020-07-01 2020-09-30 0000021665 cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2019-07-01 2019-09-30 0000021665 cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2020-01-01 2020-09-30 0000021665 cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2019-01-01 2019-09-30 0000021665 cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 cl:PetNutritionMember 2020-07-01 2020-09-30 0000021665 cl:PetNutritionMember 2019-07-01 2019-09-30 0000021665 cl:PetNutritionMember 2020-01-01 2020-09-30 0000021665 cl:PetNutritionMember 2019-01-01 2019-09-30 0000021665 us-gaap:SalesRevenueNetMember 2020-09-30 0000021665 cl:OralCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000021665 cl:OralCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000021665 cl:OralCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000021665 cl:OralCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000021665 cl:PersonalCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000021665 cl:PersonalCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000021665 cl:PersonalCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000021665 cl:PersonalCareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000021665 us-gaap:SalesRevenueNetMember cl:HomeCareMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000021665 us-gaap:SalesRevenueNetMember cl:HomeCareMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000021665 us-gaap:SalesRevenueNetMember cl:HomeCareMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000021665 us-gaap:SalesRevenueNetMember cl:HomeCareMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember cl:PetNutritionMember 2020-07-01 2020-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember cl:PetNutritionMember 2019-07-01 2019-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember cl:PetNutritionMember 2020-01-01 2020-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember cl:PetNutritionMember 2019-01-01 2019-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000021665 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000021665 srt:NorthAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:NorthAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:NorthAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:NorthAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 srt:LatinAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:LatinAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:LatinAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:LatinAmericaMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 srt:EuropeMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:EuropeMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:EuropeMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:EuropeMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 srt:AsiaPacificMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 srt:AsiaPacificMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 srt:AsiaPacificMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 srt:AsiaPacificMember us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2020-07-01 2020-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2019-07-01 2019-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2020-01-01 2020-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember cl:AfricaEurasiaMember 2019-01-01 2019-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-07-01 2020-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-07-01 2019-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2020-01-01 2020-09-30 0000021665 us-gaap:OperatingSegmentsMember cl:OralPersonalAndHomeCareMember 2019-01-01 2019-09-30 0000021665 cl:PetNutritionMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000021665 cl:PetNutritionMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000021665 cl:PetNutritionMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000021665 cl:PetNutritionMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000021665 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000021665 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000021665 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000021665 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0000021665 us-gaap:CorporateNonSegmentMember us-gaap:OperatingIncomeLossMember 2020-07-01 2020-09-30 0000021665 us-gaap:CorporateNonSegmentMember us-gaap:OperatingIncomeLossMember 2020-01-01 2020-09-30 0000021665 us-gaap:CorporateNonSegmentMember cl:GlobalGrowthandEfficiencyProgramMember us-gaap:OperatingIncomeLossMember 2020-01-01 2020-09-30 0000021665 us-gaap:CorporateNonSegmentMember cl:GlobalGrowthandEfficiencyProgramMember us-gaap:OperatingIncomeLossMember 2020-07-01 2020-09-30 0000021665 us-gaap:CorporateNonSegmentMember cl:GlobalGrowthandEfficiencyProgramMember us-gaap:OperatingIncomeLossMember 2019-07-01 2019-09-30 0000021665 us-gaap:CorporateNonSegmentMember cl:GlobalGrowthandEfficiencyProgramMember us-gaap:OperatingIncomeLossMember 2019-01-01 2019-09-30 0000021665 us-gaap:CorporateNonSegmentMember us-gaap:OperatingIncomeLossMember 2019-07-01 2019-09-30 0000021665 us-gaap:CorporateNonSegmentMember us-gaap:OperatingIncomeLossMember 2019-01-01 2019-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherCurrentAssetsMember 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherCurrentAssetsMember 2019-12-31 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherCurrentLiabilitiesMember 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherAssetsMember 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherAssetsMember 2019-12-31 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherLiabilitiesMember 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:OtherLiabilitiesMember 2019-12-31 0000021665 us-gaap:ForwardContractsMember us-gaap:OtherCurrentAssetsMember 2020-09-30 0000021665 us-gaap:ForwardContractsMember us-gaap:OtherCurrentAssetsMember 2019-12-31 0000021665 us-gaap:ForwardContractsMember us-gaap:OtherCurrentLiabilitiesMember 2020-09-30 0000021665 us-gaap:ForwardContractsMember us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0000021665 us-gaap:ForwardContractsMember us-gaap:OtherAssetsMember 2020-09-30 0000021665 us-gaap:ForwardContractsMember us-gaap:OtherAssetsMember 2019-12-31 0000021665 us-gaap:OtherLiabilitiesMember us-gaap:ForwardContractsMember 2020-09-30 0000021665 us-gaap:OtherLiabilitiesMember us-gaap:ForwardContractsMember 2019-12-31 0000021665 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2020-09-30 0000021665 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2019-12-31 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:OtherCurrentLiabilitiesMember 2020-09-30 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0000021665 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember 2020-09-30 0000021665 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember 2019-12-31 0000021665 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember 2020-09-30 0000021665 us-gaap:OtherLiabilitiesMember us-gaap:ForeignExchangeContractMember 2019-12-31 0000021665 us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember 2020-09-30 0000021665 us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember 2019-12-31 0000021665 us-gaap:CommodityContractMember us-gaap:OtherCurrentLiabilitiesMember 2020-09-30 0000021665 us-gaap:CommodityContractMember us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0000021665 us-gaap:OtherCurrentAssetsMember 2020-09-30 0000021665 us-gaap:OtherCurrentAssetsMember 2019-12-31 0000021665 us-gaap:FairValueInputsLevel2Member 2020-09-30 0000021665 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000021665 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000021665 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000021665 us-gaap:LongTermDebtMember 2020-09-30 0000021665 us-gaap:LongTermDebtMember 2019-12-31 0000021665 us-gaap:FairValueHedgingMember us-gaap:ForeignExchangeContractMember 2020-09-30 0000021665 us-gaap:FairValueHedgingMember us-gaap:DebtMember 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember 2020-09-30 0000021665 us-gaap:ForwardContractsMember us-gaap:FairValueHedgingMember 2020-09-30 0000021665 us-gaap:CommodityContractMember us-gaap:FairValueHedgingMember 2020-09-30 0000021665 us-gaap:FairValueHedgingMember 2020-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:ForeignExchangeContractMember 2020-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:DebtMember 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2020-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:ForwardContractsMember 2020-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CommodityContractMember 2020-09-30 0000021665 us-gaap:CashFlowHedgingMember 2020-09-30 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2020-09-30 0000021665 us-gaap:NetInvestmentHedgingMember us-gaap:DebtMember 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:NetInvestmentHedgingMember 2020-09-30 0000021665 us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember 2020-09-30 0000021665 us-gaap:CommodityContractMember us-gaap:NetInvestmentHedgingMember 2020-09-30 0000021665 us-gaap:NetInvestmentHedgingMember 2020-09-30 0000021665 us-gaap:FairValueHedgingMember us-gaap:ForeignExchangeContractMember 2019-12-31 0000021665 us-gaap:FairValueHedgingMember us-gaap:DebtMember 2019-12-31 0000021665 us-gaap:InterestRateContractMember us-gaap:FairValueHedgingMember 2019-12-31 0000021665 us-gaap:ForwardContractsMember us-gaap:FairValueHedgingMember 2019-12-31 0000021665 us-gaap:CommodityContractMember us-gaap:FairValueHedgingMember 2019-12-31 0000021665 us-gaap:FairValueHedgingMember 2019-12-31 0000021665 us-gaap:CashFlowHedgingMember us-gaap:ForeignExchangeContractMember 2019-12-31 0000021665 us-gaap:CashFlowHedgingMember us-gaap:DebtMember 2019-12-31 0000021665 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2019-12-31 0000021665 us-gaap:CashFlowHedgingMember us-gaap:ForwardContractsMember 2019-12-31 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CommodityContractMember 2019-12-31 0000021665 us-gaap:CashFlowHedgingMember 2019-12-31 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000021665 us-gaap:NetInvestmentHedgingMember us-gaap:DebtMember 2019-12-31 0000021665 us-gaap:InterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000021665 us-gaap:ForwardContractsMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000021665 us-gaap:CommodityContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000021665 us-gaap:NetInvestmentHedgingMember 2019-12-31 0000021665 us-gaap:InterestRateContractMember us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000021665 us-gaap:InterestRateContractMember cl:InterestIncomeExpenseNetMember 2020-07-01 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000021665 us-gaap:InterestRateContractMember cl:InterestIncomeExpenseNetMember 2019-07-01 2019-09-30 0000021665 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2020-07-01 2020-09-30 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:ForeignExchangeContractMember 2020-07-01 2020-09-30 0000021665 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:ForeignExchangeContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2020-07-01 2020-09-30 0000021665 us-gaap:CommodityContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:CommodityContractMember 2020-07-01 2020-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CommodityContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CommodityContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000021665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000021665 cl:InterestIncomeExpenseNetMember 2020-07-01 2020-09-30 0000021665 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000021665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember 2019-07-01 2019-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000021665 us-gaap:InterestRateContractMember cl:InterestIncomeExpenseNetMember 2020-01-01 2020-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000021665 us-gaap:InterestRateContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000021665 us-gaap:InterestRateContractMember cl:InterestIncomeExpenseNetMember 2019-01-01 2019-09-30 0000021665 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2020-01-01 2020-09-30 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:ForeignExchangeContractMember 2020-01-01 2020-09-30 0000021665 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:ForeignExchangeContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:ForeignExchangeContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2020-01-01 2020-09-30 0000021665 us-gaap:CommodityContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:CommodityContractMember 2020-01-01 2020-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:CashFlowHedgingMember us-gaap:CommodityContractMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember us-gaap:CashFlowHedgingMember us-gaap:CommodityContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000021665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000021665 cl:InterestIncomeExpenseNetMember 2020-01-01 2020-09-30 0000021665 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000021665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000021665 cl:InterestIncomeExpenseNetMember 2019-01-01 2019-09-30 0000021665 us-gaap:ForeignExchangeContractMember 2020-07-01 2020-09-30 0000021665 us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:ForwardContractsMember 2020-07-01 2020-09-30 0000021665 us-gaap:ForwardContractsMember 2019-07-01 2019-09-30 0000021665 us-gaap:CommodityContractMember 2020-07-01 2020-09-30 0000021665 us-gaap:CommodityContractMember 2019-07-01 2019-09-30 0000021665 us-gaap:DebtMember 2020-07-01 2020-09-30 0000021665 us-gaap:DebtMember 2019-07-01 2019-09-30 0000021665 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-09-30 0000021665 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:ForwardContractsMember 2020-01-01 2020-09-30 0000021665 us-gaap:ForwardContractsMember 2019-01-01 2019-09-30 0000021665 us-gaap:CommodityContractMember 2020-01-01 2020-09-30 0000021665 us-gaap:CommodityContractMember 2019-01-01 2019-09-30 0000021665 us-gaap:DebtMember 2020-01-01 2020-09-30 0000021665 us-gaap:DebtMember 2019-01-01 2019-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________
FORM 10-Q
_________________________
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the transition period from________ to________ .

Commission File Number: 1-644
COLGATE-PALMOLIVE COMPANY
(Exact name of registrant as specified in its charter)

Delaware | 13-1815595
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)

| 300 Park Avenue |  |  |  |
| New York, | New York |  |  | 10022 |
(Address of principal executive offices) |  | (Zip Code) |

(212) 310-2000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $1.00 par value |  | CL |  | New York Stock Exchange
0.000% Notes due 2021 |  | CL21A |  | New York Stock Exchange
0.500% Notes due 2026 |  | CL26 |  | New York Stock Exchange
1.375% Notes due 2034 |  | CL34 |  | New York Stock Exchange
0.875% Notes due 2039 |  | CL39 |  | New York Stock Exchange

NO CHANGES
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐
Non-accelerated filer | ☐ | Smaller reporting company | ☐
|  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class |  | Shares Outstanding |  | Date
Common stock, $1.00 par value |  | 857,168,831 |  | September 30, 2020

PART I. FINANCIAL INFORMATION
COLGATE-PALMOLIVE COMPANY
Condensed Consolidated Statements of Income
(Dollars in Millions Except Per Share Amounts)
(Unaudited)

| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Net sales | $ | 4,153 |  |  | $ | 3,928 |  |  | $ | 12,147 |  |  | $ | 11,678 |
Cost of sales | 1,613 |  |  | 1,612 |  |  | 4,773 |  |  | 4,767 |
Gross profit | 2,540 |  |  | 2,316 |  |  | 7,374 |  |  | 6,911 |
Selling, general and administrative expenses | 1,518 |  |  | 1,429 |  |  | 4,386 |  |  | 4,163 |
Other (income) expense, net | 4 |  |  | 31 |  |  | 72 |  |  | 125 |
Operating profit | 1,018 |  |  | 856 |  |  | 2,916 |  |  | 2,623 |
Non-service related postretirement costs | 15 |  |  | 27 |  |  | 56 |  |  | 79 |
Interest (income) expense, net | 36 |  |  | 35 |  |  | 107 |  |  | 113 |
Income before income taxes | 967 |  |  | 794 |  |  | 2,753 |  |  | 2,431 |
Provision for income taxes | 222 |  |  | 167 |  |  | 585 |  |  | 586 |
Net income including noncontrolling interests | 745 |  |  | 627 |  |  | 2,168 |  |  | 1,845 |
Less: Net income attributable to noncontrolling interests | 47 |  |  | 49 |  |  | 120 |  |  | 121 |
Net income attributable to Colgate-Palmolive Company | $ | 698 |  |  | $ | 578 |  |  | $ | 2,048 |  |  | $ | 1,724 |
Earnings per common share, basic | $ | 0.81 |  |  | $ | 0.67 |  |  | $ | 2.39 |  |  | $ | 2.00 |
Earnings per common share, diluted | $ | 0.81 |  |  | $ | 0.67 |  |  | $ | 2.38 |  |  | $ | 2.00 |

See Notes to Condensed Consolidated Financial Statements.
2

COLGATE-PALMOLIVE COMPANY
Condensed Consolidated Statements of Comprehensive Income
(Dollars in Millions)
(Unaudited)

| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Net income including noncontrolling interests | $ | 745 |  |  | $ | 627 |  |  | $ | 2,168 |  |  | $ | 1,845 |
Other comprehensive income (loss), net of tax: |  |  |  |  |  |  |
Cumulative translation adjustments | 57 |  |  | (111) |  |  | (230) |  |  | (60) |
Retirement plans and other retiree benefit adjustments | 54 |  |  | 5 |  |  | 84 |  |  | 30 |
Gains (losses) on cash flow hedges | 1 |  |  | 4 |  |  | (2) |  |  | (3) |
Total Other comprehensive income (loss), net of tax | 112 |  |  | (102) |  |  | (148) |  |  | (33) |
Total Comprehensive income including noncontrolling interests | 857 |  |  | 525 |  |  | 2,020 |  |  | 1,812 |
Less: Net income attributable to noncontrolling interests | 47 |  |  | 49 |  |  | 120 |  |  | 121 |
Less: Cumulative translation adjustments attributable to noncontrolling interests | 12 |  |  | (6) |  |  | (1) |  |  | (6) |
Total Comprehensive income attributable to noncontrolling interests | 59 |  |  | 43 |  |  | 119 |  |  | 115 |
Total Comprehensive income attributable to Colgate-Palmolive Company | $ | 798 |  |  | $ | 482 |  |  | $ | 1,901 |  |  | $ | 1,697 |

See Notes to Condensed Consolidated Financial Statements.
3

COLGATE-PALMOLIVE COMPANY
Condensed Consolidated Balance Sheets
(Dollars in Millions)
(Unaudited)

| September 30, 2020 |  | December 31, 2019
Assets |  |  |
Current Assets |  |  |
Cash and cash equivalents | $ | 989 |  |  | $ | 883 |
Receivables (net of allowances of $88 and $76, respectively) | 1,292 |  |  | 1,440 |
Inventories | 1,578 |  |  | 1,400 |
Other current assets | 508 |  |  | 456 |
Total current assets | 4,367 |  |  | 4,179 |
Property, plant and equipment: |  |  |
Cost | 8,380 |  |  | 8,580 |
Less: Accumulated depreciation | (4,874) |  |  | (4,830) |
| 3,506 |  |  | 3,750 |
Goodwill | 3,711 |  |  | 3,508 |
Other intangible assets, net | 2,838 |  |  | 2,667 |
Deferred income taxes | 208 |  |  | 177 |
Other assets | 836 |  |  | 753 |
Total assets | $ | 15,466 |  |  | $ | 15,034 |
Liabilities and Shareholders’ Equity |  |  |
Current Liabilities |  |  |
Notes and loans payable | $ | 9 |  |  | $ | 260 |
Current portion of long-term debt | 256 |  |  | 254 |
Accounts payable | 1,225 |  |  | 1,237 |
Accrued income taxes | 423 |  |  | 370 |
Other accruals | 2,568 |  |  | 1,917 |
Total current liabilities | 4,481 |  |  | 4,038 |
Long-term debt | 6,971 |  |  | 7,333 |
Deferred income taxes | 406 |  |  | 507 |
Other liabilities | 2,535 |  |  | 2,598 |
Total liabilities | 14,393 |  |  | 14,476 |
Shareholders’ Equity |  |  |
Common stock | 1,466 |  |  | 1,466 |
Additional paid-in capital | 2,837 |  |  | 2,488 |
Retained earnings | 23,052 |  |  | 22,501 |
Accumulated other comprehensive income (loss) | (4,421) |  |  | (4,273) |
Unearned compensation | (1) |  |  | (2) |
Treasury stock, at cost | (22,280) |  |  | (22,063) |
Total Colgate-Palmolive Company shareholders’ equity | 653 |  |  | 117 |
Noncontrolling interests | 420 |  |  | 441 |
Total equity | 1,073 |  |  | 558 |
Total liabilities and equity | $ | 15,466 |  |  | $ | 15,034 |

See Notes to Condensed Consolidated Financial Statements.
4

COLGATE-PALMOLIVE COMPANY
Condensed Consolidated Statements of Cash Flows
(Dollars in Millions)
(Unaudited)

| Nine Months Ended
| September 30,
| 2020 |  | 2019
Operating Activities |  |  |
Net income including noncontrolling interests | $ | 2,168 |  |  | $ | 1,845 |
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations: |  |  |
Depreciation and amortization | 400 |  |  | 386 |
Restructuring and termination benefits, net of cash | (66) |  |  | 11 |
Stock-based compensation expense | 85 |  |  | 83 |
Deferred income taxes | (124) |  |  | 79 |
Voluntary benefit plan contributions | — |  |  | (113) |
Cash effects of changes in: |  |  |
Receivables | 62 |  |  | (65) |
Inventories | (214) |  |  | (69) |
Accounts payable and other accruals | 468 |  |  | (52) |
Other non-current assets and liabilities | (23) |  |  | 58 |
Net cash provided by (used in) operations | 2,756 |  |  | 2,163 |
Investing Activities |  |  |
Capital expenditures | (249) |  |  | (226) |
Purchases of marketable securities and investments | (109) |  |  | (152) |
Proceeds from sale of marketable securities and investments | 42 |  |  | 14 |
Payment for acquisitions, net of cash acquired | (352) |  |  | (1,711) |
Net cash provided by (used in) investing activities | (668) |  |  | (2,075) |
Financing Activities |  |  |
Principal payments on debt | (3,269) |  |  | (4,184) |
Proceeds from issuance of debt | 2,500 |  |  | 6,008 |
Dividends paid | (1,162) |  |  | (1,140) |
Purchases of treasury shares | (578) |  |  | (1,024) |
Proceeds from exercise of stock options | 640 |  |  | 490 |
Purchases of non-controlling interests in subsidiaries | (99) |  |  | — |
Net cash provided by (used in) financing activities | (1,968) |  |  | 150 |
Effect of exchange rate changes on Cash and cash equivalents | (14) |  |  | (16) |
Net increase (decrease) in Cash and cash equivalents | 106 |  |  | 222 |
Cash and cash equivalents at beginning of the period | 883 |  |  | 726 |
Cash and cash equivalents at end of the period | $ | 989 |  |  | $ | 948 |
Supplemental Cash Flow Information |  |  |
Income taxes paid | $ | 606 |  |  | $ | 669 |

See Notes to Condensed Consolidated Financial Statements.
5

COLGATE-PALMOLIVE COMPANY
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(Dollars in Millions)
(Unaudited)

Three Months Ended September 30, 2020
| Colgate-Palmolive Company Shareholders’ Equity |  |
| Common Stock |  | Additional Paid-in Capital |  | Unearned Compensation |  | Treasury Stock |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss)(1) |  | Noncontrolling Interests
Balance, June 30, 2020 | $ | 1,466 |  |  | $ | 2,666 |  |  | $ | (1) |  |  | $ | (22,075) |  |  | $ | 22,731 |  |  | $ | (4,519) |  |  | $ | 464 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 698 |  |  | — |  |  | 47 |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 100 |  |  | 12 |
Dividends ($0.44 per share) | — |  |  | — |  |  | — |  |  | — |  |  | (379) |  |  | — |  |  | — |
Stock-based compensation expense | — |  |  | 53 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for stock options | — |  |  | 130 |  |  | — |  |  | 132 |  |  | — |  |  | — |  |  | — |
Shares issued for restricted stock units | — |  |  | (13) |  |  | — |  |  | 13 |  |  | — |  |  | — |  |  | — |
Treasury stock acquired | — |  |  | — |  |  | — |  |  | (350) |  |  | — |  |  | — |  |  | — |
Noncontrolling interests acquired | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (99) |
Other | — |  |  | 1 |  |  | — |  |  | — |  |  | 2 |  |  | (2) |  |  | (4) |
Balance, September 30, 2020 | $ | 1,466 |  |  | $ | 2,837 |  |  | $ | (1) |  |  | $ | (22,280) |  |  | $ | 23,052 |  |  | $ | (4,421) |  |  | $ | 420 |

Three Months Ended September 30, 2019
| Colgate-Palmolive Company Shareholders’ Equity |  |
| Common Stock |  | Additional Paid-in Capital |  | Unearned Compensation |  | Treasury Stock |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss)(1) |  | Noncontrolling Interests
Balance, June 30, 2019 | $ | 1,466 |  |  | $ | 2,338 |  |  | $ | (3) |  |  | $ | (21,682) |  |  | $ | 21,653 |  |  | $ | (4,119) |  |  | $ | 337 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 578 |  |  | — |  |  | 49 |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (96) |  |  | (6) |
Dividends ($0.43 per share) | — |  |  | — |  |  | — |  |  | — |  |  | (370) |  |  | — |  |  | (2) |
Stock-based compensation expense | — |  |  | 49 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for stock options | — |  |  | 93 |  |  | — |  |  | 128 |  |  | — |  |  | — |  |  | — |
Shares issued for restricted stock units | — |  |  | (14) |  |  | — |  |  | 14 |  |  | — |  |  | — |  |  | — |
Treasury stock acquired | — |  |  | — |  |  | — |  |  | (360) |  |  | — |  |  | — |  |  | — |
Noncontrolling interests assumed through acquisition | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 120 |
Other | — |  |  | — |  |  | 2 |  |  | — |  |  | (1) |  |  | — |  |  | — |
Balance, September 30, 2019 | $ | 1,466 |  |  | $ | 2,466 |  |  | $ | (1) |  |  | $ | (21,900) |  |  | $ | 21,860 |  |  | $ | (4,215) |  |  | $ | 498 |

(1) Accumulated other comprehensive income (loss) includes cumulative translation losses of $3,357 at September 30, 2020 ($3,209 at September 30, 2019) and $3,402 at June 30, 2020 ($3,104 at June 30, 2019), respectively, and unrecognized retirement plan and other retiree benefits costs of $1,054 at September 30, 2020 ($1,008 at September 30, 2019) and $1,108 at June 30, 2020 ($1,013 at June 30, 2019), respectively.
See Notes to Condensed Consolidated Financial Statements.
6

COLGATE-PALMOLIVE COMPANY
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(Dollars in Millions)
(Unaudited)

Nine Months Ended September 30, 2020
| Colgate-Palmolive Company Shareholders’ Equity |  |
| Common Stock |  | Additional Paid-in Capital |  | Unearned Compensation |  | Treasury Stock |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss)(1) |  | Noncontrolling Interests
Balance, December 31, 2019 | $ | 1,466 |  |  | $ | 2,488 |  |  | $ | (2) |  |  | $ | (22,063) |  |  | $ | 22,501 |  |  | $ | (4,273) |  |  | $ | 441 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 2,048 |  |  | — |  |  | 120 |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (147) |  |  | (1) |
Dividends ($1.75 per share)* | — |  |  | — |  |  | — |  |  | — |  |  | (1,503) |  |  | — |  |  | (37) |
Stock-based compensation expense | — |  |  | 85 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for stock options | — |  |  | 290 |  |  | — |  |  | 329 |  |  | — |  |  | — |  |  | — |
Shares issued for restricted stock units | — |  |  | (30) |  |  | — |  |  | 30 |  |  | — |  |  | — |  |  | — |
Treasury stock acquired | — |  |  | — |  |  | — |  |  | (578) |  |  | — |  |  | — |  |  | — |
Noncontrolling interests acquired | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (99) |
Other | — |  |  | 4 |  |  | 1 |  |  | 2 |  |  | 6 |  |  | (1) |  |  | (4) |
Balance, September 30, 2020 | $ | 1,466 |  |  | $ | 2,837 |  |  | $ | (1) |  |  | $ | (22,280) |  |  | $ | 23,052 |  |  | $ | (4,421) |  |  | $ | 420 |

Nine Months Ended September 30, 2019
| Colgate-Palmolive Company Shareholders’ Equity |  |
| Common Stock |  | Additional Paid-in Capital |  | Unearned Compensation |  | Treasury Stock |  | Retained Earnings |  | Accumulated Other Comprehensive Income (Loss)(1) |  | Noncontrolling Interests
Balance, December 31, 2018 | $ | 1,466 |  |  | $ | 2,204 |  |  | $ | (3) |  |  | $ | (21,196) |  |  | $ | 21,615 |  |  | $ | (4,188) |  |  | $ | 299 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | 1,724 |  |  | — |  |  | 121 |
Other comprehensive income (loss), net of tax | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (27) |  |  | (6) |
Dividends ($1.71 per share)* | — |  |  | — |  |  | — |  |  | — |  |  | (1,473) |  |  | — |  |  | (36) |
Stock-based compensation expense | — |  |  | 83 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for stock options | — |  |  | 207 |  |  | — |  |  | 290 |  |  | — |  |  | — |  |  | — |
Shares issued for restricted stock units | — |  |  | (28) |  |  | — |  |  | 28 |  |  | — |  |  | — |  |  | — |
Treasury stock acquired | — |  |  | — |  |  | — |  |  | (1,024) |  |  | — |  |  | — |  |  | — |
Noncontrolling interests assumed through acquisition | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 120 |
Other | — |  |  | — |  |  | 2 |  |  | 2 |  |  | (6) |  |  | — |  |  | — |
Balance, September 30, 2019 | $ | 1,466 |  |  | $ | 2,466 |  |  | $ | (1) |  |  | $ | (21,900) |  |  | $ | 21,860 |  |  | $ | (4,215) |  |  | $ | 498 |

(1) Accumulated other comprehensive income (loss) includes cumulative translation losses of $3,357 at September 30, 2020 ($3,209 at September 30, 2019) and $3,128 at December 31, 2019 ($3,155 at December 31, 2018), respectively, and unrecognized retirement plan and other retiree benefits costs of $1,054 at September 30, 2020 ($1,008 at September 30, 2019) and $1,138 at December 31, 2019 ($1,038 at December 31, 2018), respectively.
* Two dividends were declared in each of the first quarters of 2020 and 2019
See Notes to Condensed Consolidated Financial Statements.
7

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
1. Basis of Presentation
The Condensed Consolidated Financial Statements reflect all normal recurring adjustments which, in management’s opinion, are necessary for a fair statement of the results for interim periods. Results of operations for interim periods may not be representative of results to be expected for a full year. Colgate-Palmolive Company (together with its subsidiaries, the “Company” or “Colgate”) reclassifies certain prior year amounts, as applicable, to conform to the current year presentation.
For a complete set of financial statement notes, including the Company’s significant accounting policies, refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (the “SEC”).
2. Use of Estimates
Provisions for certain expenses, including income taxes, advertising and consumer promotion, are based on full year assumptions and are included in the accompanying Condensed Consolidated Financial Statements in proportion with estimated annual tax rates, the passage of time or estimated annual sales, as applicable.
3. Recent Accounting Pronouncements
In March 2020, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU provides optional expedients and exceptions for applying generally accepted accounting principles (“GAAP”) to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This new guidance was effective upon issuance of this ASU for contract modifications and hedging relationships on a prospective basis and is not expected to have a material impact on the Company’s Consolidated Financial Statements.
In March 2020, the FASB issued ASU No. 2020-03, “Codification to Financial Instruments.” This ASU improves and clarifies various financial instruments topics, including the current expected credit losses (“CECL”) standard issued in 2016. The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments related to Issue 1, Issue 2, Issue 4 and Issue 5 were effective upon issuance of this update. The amendments related to Issue 3, Issue 6 and Issue 7 were effective for the Company beginning on January 1, 2020. The new guidance did not have a material impact on the Company’s Consolidated Financial Statements.
In January 2020, the FASB issued ASU No. 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323) and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. This new guidance is effective for the Company beginning on January 1, 2021, with early adoption permitted. This new guidance is not expected to have a material impact on the Company’s Consolidated Financial Statements.
In December 2019, the FASB issued ASU No. 2019-12, “Income taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and also clarifies and amends existing guidance to improve consistent application. This new guidance is effective for the Company beginning on January 1, 2021, with early adoption permitted. This new guidance is not expected to have a material impact on the Company’s Consolidated Financial Statements.
In April 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825).” This ASU clarifies three topics related to financial instruments accounting. This new guidance was effective for the Company beginning on January 1, 2020. The new guidance did not have a material impact on the Company’s Consolidated Financial Statements.
8

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” This new guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This new guidance was effective for the Company beginning on January 1, 2020 and did not have a material impact on the Company’s Consolidated Financial Statements.
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” eliminating the requirement to calculate implied fair value, essentially eliminating step two from the goodwill impairment test. The new standard requires goodwill impairment to be based upon the results of step one of the impairment test, which is defined as the excess of the carrying value of a reporting unit over its fair value. Any impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The standard was effective for the Company on a prospective basis beginning on January 1, 2020 and did not have a material impact on the Company’s Consolidated Financial Statements.
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326) Codification Improvements to Financial Instruments-Credit Losses (Topic 326).” Subsequent updates were released in November 2018 (ASU No. 2018-19), November 2019 (ASU No. 2019-10 and 2019-11) and February 2020 (ASU No. 2020-02) that provided additional guidance on this Topic. This ASU introduces the CECL model, which will require an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. The Company adopted the new standard, which primarily impacts the Company’s trade receivables and related methodology for assessing the collectability of its customer accounts, on January 1, 2020, on a “modified retrospective” basis. The adoption of this ASU did not have a material impact on the Company’s Consolidated Financial Statements.
9

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
4. Acquisitions
Hello Products LLC
On January 31, 2020, the Company acquired Hello Products LLC, an oral care business, for cash consideration of $351. The acquisition was financed with a combination of debt and cash. This acquisition is part of the Company’s strategy to focus on high growth segments within its Oral Care, Personal Care and Pet Nutrition businesses.
The total purchase price consideration of $351 has been allocated to the net assets acquired based on their respective preliminary estimated fair values as follows:

Receivables | $ | 11 |
Inventories | 13 |
Other assets and liabilities, net | (4) |
Other intangible assets | 160 |
Goodwill | 171 |
Fair value of net assets acquired | $ | 351 |

Other intangible assets acquired include trademarks, valued at $115, which are considered to have a finite useful life of 25 years, and customer relationships valued at $45, which are considered to have a finite useful life of 17 years. Goodwill of $171 was allocated to the North America segment. The Company expects that goodwill will be deductible for tax purposes.
The preliminary estimates of the fair value of identifiable assets acquired and liabilities assumed are subject to revisions, which may result in additional adjustments to the preliminary values discussed above. The Company expects to finalize the purchase price allocation no later than the first quarter of 2021.
Pro forma results of operations have not been presented as the impact on the Company’s Condensed Consolidated Financial Statements is not material.
Laboratoires Filorga Cosmétiques (“Filorga”)
On September 19, 2019, the Company acquired the Filorga skin health business ("Filorga") for cash consideration of €1,516 (approximately $1,674), which included interest on the equity purchase price, plus additional consideration of €32 (approximately $38), the majority of which related to repayment of loans from former shareholders of Filorga. Filorga is a premium anti-aging skin health brand focused primarily on facial care. This acquisition is part of the Company’s strategy to focus on high growth segments within its Oral Care, Personal Care and Pet Nutrition businesses, including by expanding its portfolio in premium skin health.
10

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
The total purchase price consideration of $1,712 has been allocated to the net assets acquired based on their respective preliminary estimated fair values as follows:

Cash | $ | 30 |
Receivables | 53 |
Inventories | 70 |
Other current assets | 18 |
Other intangible assets | 1,051 |
Goodwill | 923 |
Other current liabilities | (67) |
Deferred income taxes | (276) |
Noncontrolling interests | (90) |
Fair value of net assets acquired | $ | 1,712 |

Other intangible assets acquired include trademarks of $774, which are considered to have an indefinite useful life, and customer relationships of $277, which are considered to have a finite useful life of 14 years. Goodwill of $923 was allocated to the Europe segment. Goodwill will not be deductible for tax purposes.
In the third quarter of 2020, the Company completed the purchase of the outstanding non-controlling interest of Filorga’s joint venture based in Hong Kong and covering the Hong Kong and China markets, for approximately €85 (approximately $99) in cash.
Pro forma results of operations have not been presented as the impact on the Company’s Condensed Consolidated Financial Statements is not material.
Nigeria Joint Venture
On August 15, 2019, the Company acquired a 51% controlling interest in Colgate Tolaram Pte. Ltd., a joint venture which owns the Nigeria-based Hypo Homecare Products Limited, for $31.
Pro forma results of operations have not been presented as the impact on the Company’s Condensed Consolidated Financial Statements is not material.
11

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
5. Restructuring and Related Implementation Charges
The Company’s restructuring program (the “Global Growth and Efficiency Program”), which commenced in the fourth quarter of 2012, concluded on December 31, 2019. Initiatives under the Global Growth and Efficiency Program fit within the program’s three focus areas of expanding commercial hubs, extending shared business services and streamlining global functions and optimizing the global supply chain and facilities.
During the three months ended September 30, 2020, the Company adjusted the accrual balances related to certain projects approved prior to the conclusion of the Global Growth and Efficiency Program to reflect its revised estimate of remaining liabilities. This adjustment resulted in a reduction of $16 ($13 after-tax), of which $3 was recorded in Selling, general and administrative expenses and $13 was recorded in Other (income) expense, net. No new restructuring projects were approved for implementation during the nine months ended September 30, 2020.
For the three and nine months ended September 30, 2019 restructuring and implementation-related charges are reflected in the income statement as follows:

|  | Three Months Ended |  | Nine Months Ended
|  | September 30, 2019 |  | September 30, 2019
Cost of sales |  | $ | 1 |  |  | $ | 9 |
Selling, general and administrative expenses |  | 28 |  |  | 42 |
Other (income) expense, net |  | (3) |  |  | 43 |
Non-service related postretirement costs |  | 1 |  |  | 4 |
Total Global Growth and Efficiency Program charges, pretax |  | $ | 27 |  |  | $ | 98 |
Total Global Growth and Efficiency Program charges, aftertax |  | $ | 22 |  |  | $ | 75 |

Restructuring and implementation-related charges in the preceding table and the adjustment recorded in the third quarter of 2020 were recorded in the Corporate segment as these decisions were predominantly centrally directed and controlled and were not included in internal measures of segment operating performance.
12

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
The following tables summarize the activity for restructuring accrual:

|  |  |  |  |  |  |  |  |  | Three Months Ended September 30, 2020
Balance at June 30, 2020 |  |  |  |  |  |  |  |  |  | $ | 64 |
Charges (Benefits) |  |  |  |  |  |  |  |  |  | (16) |
Cash payments |  |  |  |  |  |  |  |  |  | (15) |
Charges against assets |  |  |  |  |  |  |  |  |  | — |
Foreign exchange |  |  |  |  |  |  |  |  |  | 1 |
Other |  |  |  |  |  |  |  |  |  | — |
Balance at September 30, 2020 |  |  |  |  |  |  |  |  |  | $ | 34 |

|  |  |  |  |  |  |  |  |  | Nine Months Ended September 30, 2020
Balance at December 31, 2019 |  |  |  |  |  |  |  |  |  | $ | 100 |
Charges (Benefits) |  |  |  |  |  |  |  |  |  | (16) |
Cash payments |  |  |  |  |  |  |  |  |  | (50) |
Charges against assets |  |  |  |  |  |  |  |  |  | — |
Foreign exchange |  |  |  |  |  |  |  |  |  | — |
Other |  |  |  |  |  |  |  |  |  | — |
Balance at September 30, 2020 |  |  |  |  |  |  |  |  |  | $ | 34 |

13

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
6. Inventories
Inventories by major class are as follows:

| September 30, 2020 |  | December 31, 2019
Raw materials and supplies | $ | 390 |  |  | $ | 305 |
Work-in-process | 48 |  |  | 49 |
Finished goods | 1,190 |  |  | 1,056 |
Total Inventories, net | $ | 1,628 |  |  | $ | 1,410 |
Non-current inventory, net | $ | (50) |  |  | $ | (10) |
Current Inventories, net | $ | 1,578 |  |  | $ | 1,400 |

7. Earnings Per Share
For the three months ended September 30, 2020 and 2019, earnings per share were as follows:

| Three Months Ended
| September 30, 2020 |  | September 30, 2019
| Net income attributable to Colgate-Palmolive Company |  | Shares (millions) |  | Per Share |  | Net income attributable to Colgate-Palmolive Company |  | Shares (millions) |  | Per Share
Basic EPS | $ | 698 |  |  | 859.0 |  |  | $ | 0.81 |  |  | $ | 578 |  |  | 858.7 |  |  | $ | 0.67 |
Stock options and restricted stock units |  |  | 2.8 |  |  |  |  |  |  | 2.5 |  |  |
Diluted EPS | $ | 698 |  |  | 861.8 |  |  | $ | 0.81 |  |  | $ | 578 |  |  | 861.2 |  |  | $ | 0.67 |

For the three months ended September 30, 2020 and 2019, the average number of stock options and restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 2,693,996 and 16,963,201, respectively.
For the nine months ended September 30, 2020 and 2019, earnings per share were as follows:

| Nine Months Ended
| September 30, 2020 |  | September 30, 2019
| Net income attributable to Colgate-Palmolive Company |  | Shares (millions) |  | Per Share |  | Net income attributable to Colgate-Palmolive Company |  | Shares (millions) |  | Per Share
Basic EPS | $ | 2,048 |  |  | 857.7 |  |  | $ | 2.39 |  |  | $ | 1,724 |  |  | 860.1 |  |  | $ | 2.00 |
Stock options and restricted stock units |  |  | 1.8 |  |  |  |  |  |  | 2.3 |  |  |
Diluted EPS | $ | 2,048 |  |  | 859.5 |  |  | $ | 2.38 |  |  | $ | 1,724 |  |  | 862.4 |  |  | $ | 2.00 |

For the nine months ended September 30, 2020 and 2019, the average number of stock options and restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 15,862,643 and 18,818,149, respectively.
Basic and diluted earnings per share are computed independently for each quarter and any year-to-date period presented. As a result of changes in the number of shares outstanding during the year and rounding, the sum of the quarters’ earnings per share may not necessarily equal the earnings per share for any year-to-date period.
14

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
8. Other Comprehensive Income (Loss)
Additions to and reclassifications out of Accumulated other comprehensive income (loss) attributable to the Company for the three months ended September 30, 2020 and 2019 were as follows:

|  | 2020 |  | 2019
|  | Pretax |  | Net of Tax |  | Pretax |  | Net of Tax
Cumulative translation adjustments |  | $ | 5 |  |  | $ | 45 |  |  | $ | (83) |  |  | $ | (105) |
Retirement plans and other retiree benefits: |  |  |  |  |  |  |  |
Net actuarial gain (loss) and prior service costs arising during the period |  | 53 |  |  | 41 |  |  | (14) |  |  | (10) |
Amortization of net actuarial loss, transition and prior service costs (1) |  | 15 |  |  | 13 |  |  | 19 |  |  | 15 |
Retirement plans and other retiree benefits adjustments |  | 68 |  |  | 54 |  |  | 5 |  |  | 5 |
Cash flow hedges: |  |  |  |  |  |  |  |
Unrealized gains (losses) on cash flow hedges |  | (1) |  |  | (1) |  |  | 6 |  |  | 5 |
Reclassification of (gains) losses into net earnings on cash flow hedges (2) |  | 2 |  |  | 2 |  |  | (1) |  |  | (1) |
Gains (losses) on cash flow hedges |  | 1 |  |  | 1 |  |  | 5 |  |  | 4 |
Total Other comprehensive income (loss) |  | $ | 74 |  |  | $ | 100 |  |  | $ | (73) |  |  | $ | (96) |

(1) These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details.
(2) These (gains) losses are reclassified into Cost of sales. See Note 13, Fair Value Measurements and Financial Instruments for additional details.
There were no tax impacts on Other comprehensive income (loss) (“OCI”) attributable to Noncontrolling interests.
Additions to and reclassifications out of Accumulated other comprehensive income (loss) attributable to the Company for the nine months ended September 30, 2020 and 2019 were as follows:

|  | 2020 |  | 2019
|  | Pretax |  | Net of Tax |  | Pretax |  | Net of Tax
Cumulative translation adjustments |  | $ | (288) |  |  | $ | (229) |  |  | $ | (33) |  |  | $ | (54) |
Retirement plans and other retiree benefits: |  |  |  |  |  |  |  |
Net actuarial gain (loss) and prior service costs arising during the period |  | 55 |  |  | 42 |  |  | (15) |  |  | (11) |
Amortization of net actuarial loss, transition and prior service costs (1) |  | 55 |  |  | 42 |  |  | 54 |  |  | 41 |
Retirement plans and other retiree benefits adjustments |  | 110 |  |  | 84 |  |  | 39 |  |  | 30 |
Cash flow hedges: |  |  |  |  |  |  |  |
Unrealized gains (losses) on cash flow hedges |  | 2 |  |  | 1 |  |  | 3 |  |  | 2 |
Reclassification of (gains) losses into net earnings on cash flow hedges (2) |  | (4) |  |  | (3) |  |  | (6) |  |  | (5) |
Gains (losses) on cash flow hedges |  | (2) |  |  | (2) |  |  | (3) |  |  | (3) |
Total Other comprehensive income (loss) |  | $ | (180) |  |  | $ | (147) |  |  | $ | 3 |  |  | $ | (27) |

(1) These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details.
(2) These (gains) losses are reclassified into Cost of sales. See Note 13, Fair Value Measurements and Financial Instruments for additional details.
There were no tax impacts on OCI attributable to Noncontrolling interests.
15

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
9. Retirement Plans and Other Retiree Benefits
Components of Net periodic benefit cost for the three and nine months ended September 30, 2020 and 2019 were as follows:

| Three Months Ended September 30, 2020
| Pension Benefits |  | Other Retiree Benefits
| United States |  | International |  |  |  |
| 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019
Service cost | $ | — |  |  | $ | 1 |  |  | $ | 4 |  |  | $ | 3 |  |  | $ | 3 |  |  | $ | 4 |
Interest cost | 20 |  |  | 22 |  |  | 5 |  |  | 6 |  |  | 10 |  |  | 15 |
Expected return on plan assets | (29) |  |  | (29) |  |  | (6) |  |  | (4) |  |  | — |  |  | (2) |
Amortization of actuarial loss (gain) | 10 |  |  | 14 |  |  | 2 |  |  | 1 |  |  | 3 |  |  | 4 |
Net periodic benefit cost | $ | 1 |  |  | $ | 8 |  |  | $ | 5 |  |  | $ | 6 |  |  | $ | 16 |  |  | $ | 21 |

| Nine Months Ended September 30, 2020
| Pension Benefits |  | Other Retiree Benefits
| United States |  | International |  |  |  |
| 2020 |  | 2019 |  | 2020 |  | 2019 |  | 2020 |  | 2019
Service cost | $ | — |  |  | $ | 1 |  |  | $ | 11 |  |  | $ | 10 |  |  | $ | 14 |  |  | $ | 11 |
Interest cost | 57 |  |  | 68 |  |  | 14 |  |  | 16 |  |  | 29 |  |  | 35 |
Expected return on plan assets | (83) |  |  | (78) |  |  | (15) |  |  | (13) |  |  | (1) |  |  | (3) |
Amortization of actuarial loss (gain) | 34 |  |  | 39 |  |  | 7 |  |  | 6 |  |  | 14 |  |  | 9 |
Net periodic benefit cost | $ | 8 |  |  | $ | 30 |  |  | $ | 17 |  |  | $ | 19 |  |  | $ | 56 |  |  | $ | 52 |

For the nine months ended September 30, 2020 and 2019, the Company made voluntary contributions to its U.S. postretirement plans of $0 and $113, respectively.
16

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
10. Income Taxes
The provision for income taxes for the nine months ended September 30, 2020 includes $71 of income tax benefits recorded on a discrete period basis of which $45 relates to previously recorded foreign withholding taxes and $26 relates to a previously recorded valuation allowance against a deferred tax asset. As more fully described below, both items were previously recorded in connection with the charge recorded by the Company in 2017 and revised in 2018 related to the Tax Cuts and Jobs Acts (the “TCJA”).
As part of the previously recorded charge for the TCJA, the Company had provided for foreign withholding taxes expected to be paid on the remittance of earnings from certain overseas subsidiaries no longer deemed indefinitely reinvested. As a result of a recent reorganization of the ownership structure of certain foreign subsidiaries, the Company determined that no withholding taxes are due on the remittance by certain subsidiaries of earnings previously deemed reinvested and, accordingly, in the first quarter of 2020, reversed $45 of previously recorded foreign withholding taxes.
Also as part of the previously recorded charge for the TCJA, the Company provided a valuation allowance against a deferred tax asset related to foreign tax credit carry-forwards that the Company did not expect to be able to use due to changes made by the TCJA. As a result of a new operating structure being implemented within one of the Company’s divisions, the Company believes the use of these foreign tax credit carry-forwards will not be limited in the future and, accordingly, in the first quarter of 2020, reversed the previously recorded valuation allowance of $26.
11. Contingencies
As a global company serving consumers in more than 200 countries and territories, the Company is routinely subject to a wide variety of legal proceedings. These include disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. Management proactively reviews and monitors the Company’s exposure to, and the impact of, environmental matters. The Company is party to various environmental matters and, as such, may be responsible for all or a portion of the cleanup, restoration and post-closure monitoring of several sites.
The Company establishes accruals for loss contingencies when it has determined that a loss is probable and that the amount of loss, or range of loss, can be reasonably estimated. Any such accruals are adjusted thereafter as appropriate to reflect changes in circumstances.
The Company also determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that a loss is reasonably possible and it is able to determine such estimates. For those matters disclosed below for which the amount of any potential losses can be reasonably estimated, the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is $0 to approximately $400 (based on current exchange rates). The estimates included in this amount are based on the Company’s analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate amount may not represent the ultimate loss to the Company. Thus, the Company’s exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above.
Based on current knowledge, management does not believe that the ultimate resolution of loss contingencies arising from the matters discussed herein will have a material effect on the Company’s consolidated financial position or its ongoing results of operations or cash flows. However, in light of the inherent uncertainties noted above, an adverse outcome in one or more matters could be material to the Company’s results of operations or cash flows for any particular quarter or year.
17

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
Brazilian Matters
There are certain tax and civil proceedings outstanding, as described below, related to the Company’s 1995 acquisition of the Kolynos oral care business from Wyeth (the “Seller”).
The Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company’s Brazilian subsidiary for certain years in connection with the financing of the Kolynos acquisition. The tax assessments with interest, penalties and any court-mandated fees, at the current exchange rate, are approximately $103. This amount includes additional assessments received from the Brazilian internal revenue authority in April 2016 relating to net operating loss carryforwards used by the Company’s Brazilian subsidiary to offset taxable income that had also been deducted from the authority’s original assessments. The Company has been disputing the disallowances by appealing the assessments since October 2001.
In each of September 2015, February 2017, June 2018, April 2019 and September 2020, the Company lost an administrative appeal and subsequently filed an appeal in Brazilian federal court. Currently, there are five appeals pending in the Brazilian federal court. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the disallowances are without merit and that the Company should ultimately prevail. The Company is challenging these disallowances vigorously.
In July 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda. (the Brazilian subsidiary of the Seller) and the Company, as represented by its Brazilian subsidiary, in the 6th. Lower Federal Court in the City of São Paulo, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller’s Brazilian subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company’s Brazilian subsidiary jointly and severally liable for any tax due from the Seller’s Brazilian subsidiary. The case has been pending since 2002, and the Lower Federal Court has not issued a decision. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the Company should ultimately prevail in this action. The Company is challenging this action vigorously.
In December 2005, the Brazilian internal revenue authority issued to the Company’s Brazilian subsidiary a tax assessment with interest, penalties and any court-mandated fees of approximately $46, at the current exchange rate, based on a claim that certain purchases of U.S. Treasury bills by the subsidiary and their subsequent disposition during the period 2000 to 2001 were subject to a tax on foreign exchange transactions. The Company had been disputing the assessment within the internal revenue authority’s administrative appeals process. However, in November 2015, the Superior Chamber of Administrative Tax Appeals denied the Company’s final administrative appeal, and the Company has filed a lawsuit in the Brazilian federal court. In the event the Company is unsuccessful in this lawsuit, further appeals are available within the Brazilian federal courts. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the tax assessment is without merit and that the Company should ultimately prevail. The Company is challenging this assessment vigorously.
18

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
Competition Matter
Certain of the Company’s subsidiaries were historically subject to actions and, in some cases, fines, by governmental authorities in a number of countries related to alleged competition law violations. Substantially all of these matters also involved other consumer goods companies and/or retail customers. The Company’s policy is to comply with antitrust and competition laws and, if a violation of any such laws is found, to take appropriate remedial action and to cooperate fully with any related governmental inquiry. The status as of September 30, 2020 of such competition law matters pending against the Company during the nine months ended September 30, 2020 is set forth below.
▪In July 2014, the Greek competition law authority issued a statement of objections alleging a restriction of parallel imports into Greece. The Company responded to this statement of objections. In July 2017, the Company received the decision from the Greek competition law authority in which the Company was fined $11. The Company appealed the decision to the Greek courts. In April 2019, the Greek courts affirmed the judgment against the Company’s Greek subsidiary, but reduced the fine to $10.5 and dismissed the case against Colgate-Palmolive Company. The Company’s Greek subsidiary and the Greek competition authority have appealed the decision to the Greek Supreme Court.
Talcum Powder Matters
The Company has been named as a defendant in civil actions alleging that certain talcum powder products that were sold prior to 1996 were contaminated with asbestos. Most of these actions involve a number of co-defendants from a variety of different industries, including suppliers of asbestos and manufacturers of products that, unlike the Company’s products, were designed to contain asbestos. As of September 30, 2020, there were 139 individual cases pending against the Company in state and federal courts throughout the United States, as compared to 128 cases as of June 30, 2020 and 121 cases as of December 31, 2019. During the three months ended September 30, 2020, 20 new cases were filed and nine cases were resolved by voluntary dismissal, settlement or dismissal by the court. During the nine months ended September 30, 2020, 37 new cases were filed and 18 cases were resolved by voluntary dismissal, settlement or dismissal by the court. In addition, during the nine months ended September 30, 2020, one case that was previously dismissed by the trial court was affirmed on appeal and is now closed. The value of the settlements in the quarter and the year-to-date period presented was not material, either individually or in the aggregate, to each such period’s results of operations.
A significant portion of the Company’s costs incurred in defending and resolving these claims has been, and the Company believes will continue to be, covered by insurance policies issued by several primary, excess and umbrella insurance carriers, subject to deductibles, exclusions, retentions and policy limits.
While the Company and its legal counsel believe that these cases are without merit and intend to challenge them vigorously, there can be no assurances regarding the ultimate resolution of these matters. With the exception of one case where the Company received an adverse jury verdict in the second quarter of 2019 that the Company has appealed, the range of reasonably possible losses in excess of accrued liabilities disclosed above does not include any amount relating to these cases because the amount of any possible losses from such cases currently cannot be reasonably estimated.
ERISA Matter
In June 2016, a putative class action claiming that residual annuity payments made to certain participants in the Colgate-Palmolive Company Employees’ Retirement Income Plan (the “Plan”) did not comply with the Employee Retirement Income Security Act was filed against the Plan, the Company and certain individuals (the “Company Defendants”) in the United States District Court for the Southern District of New York (the “Court”). The relief sought includes recalculation of benefits, pre- and post-judgment interest and attorneys’ fees. This action was certified as a class action in July 2017. In July 2020, the Court granted in part and denied in part the Company Defendants’ motion for summary judgment and dismissed certain claims on consent of the parties. In August 2020, the Court granted the plaintiffs’ motion for summary judgment on the remaining claims. The Company and the Plan are contesting this action vigorously and, in September 2020, appealed to the United States Court of Appeals for the Second Circuit.
19

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
12. Segment Information
The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition.
The operations of the Oral, Personal and Home Care product segment are managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of operating segment performance because it excludes the impact of Corporate-driven decisions related to interest expense and income taxes.
The accounting policies of the operating segments are generally the same as those described in Note 2, Summary of Significant Accounting Policies to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Intercompany sales have been eliminated. Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs and gains and losses on sales of non-core product lines and assets. The Company reports these items within Corporate operations as they relate to Corporate-based responsibilities and decisions and are not included in the internal measures of segment operating performance used by the Company to measure the underlying performance of the operating segments.
Net sales by segment were as follows:

| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Net sales |  |  |  |  |  |  |
Oral, Personal and Home Care |  |  |  |  |  |  |
North America | $ | 923 |  |  | $ | 869 |  |  | $ | 2,801 |  |  | $ | 2,568 |
Latin America | 837 |  |  | 881 |  |  | 2,531 |  |  | 2,700 |
Europe | 712 |  |  | 607 |  |  | 2,004 |  |  | 1,798 |
Asia Pacific | 722 |  |  | 690 |  |  | 1,980 |  |  | 2,035 |
Africa/Eurasia | 255 |  |  | 248 |  |  | 736 |  |  | 732 |
Total Oral, Personal and Home Care | 3,449 |  |  | 3,295 |  |  | 10,052 |  |  | 9,833 |
Pet Nutrition | 704 |  |  | 633 |  |  | 2,095 |  |  | 1,845 |
Total Net sales | $ | 4,153 |  |  | $ | 3,928 |  |  | $ | 12,147 |  |  | $ | 11,678 |

Approximately 70% of the Company’s Net sales are generated from markets outside the U.S., with approximately 45% of the Company’s Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe).
20

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
The Company’s Net sales of Oral, Personal and Home Care and Pet Nutrition products accounted for the following percentages of the Company’s Net sales:

| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Net sales |  |  |  |  |  |  |
Oral Care | 44 | % |  | 46 | % |  | 43 | % |  | 46 | %
Personal Care | 21 | % |  | 20 | % |  | 21 | % |  | 20 | %
Home Care | 18 | % |  | 18 | % |  | 19 | % |  | 18 | %
Pet Nutrition | 17 | % |  | 16 | % |  | 17 | % |  | 16 | %
Total Net sales | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %

Operating profit by segment was as follows:

| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Operating profit |  |  |  |  |  |  |
Oral, Personal and Home Care |  |  |  |  |  |  |
North America | $ | 242 |  |  | $ | 248 |  |  | $ | 753 |  |  | $ | 750 |
Latin America | 250 |  |  | 235 |  |  | 728 |  |  | 718 |
Europe | 169 |  |  | 153 |  |  | 482 |  |  | 452 |
Asia Pacific | 222 |  |  | 193 |  |  | 559 |  |  | 557 |
Africa/Eurasia | 61 |  |  | 48 |  |  | 174 |  |  | 141 |
Total Oral, Personal and Home Care | 944 |  |  | 877 |  |  | 2,696 |  |  | 2,618 |
Pet Nutrition | 196 |  |  | 169 |  |  | 588 |  |  | 501 |
Corporate | (122) |  |  | (190) |  |  | (368) |  |  | (496) |
Total Operating profit | $ | 1,018 |  |  | $ | 856 |  |  | $ | 2,916 |  |  | $ | 2,623 |

For the three and nine months ended September 30, 2020, Corporate Operating profit (loss) included acquisition-related costs of $0 and $6, respectively, and benefits of $16 in both periods resulting from the Global Growth and Efficiency Program, which ended on December 31, 2019.
For the three and nine months ended September 30, 2019, Corporate Operating profit (loss) included charges of $26 and $94, respectively, resulting from the Global Growth and Efficiency Program, which ended on December 31, 2019 and acquisition-related costs of $18 in both periods.
21

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
13. Fair Value Measurements and Financial Instruments
The Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material, as it is the Company’s policy to contract only with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations.
The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a global basis by utilizing a number of techniques, including working capital management, sourcing strategies, selling price increases, selective borrowings in local currencies and entering into selective derivative instrument transactions, issued with standard features, in accordance with the Company’s treasury and risk management policies, which prohibit the use of derivatives for speculative purposes and leveraged derivatives for any purpose. It is the Company’s policy to enter into derivative instrument contracts with terms that match the underlying exposure being hedged.
The Company’s derivative instruments include interest rate swap contracts, forward-starting interest rate swaps, foreign currency contracts and commodity contracts. The Company utilizes interest rate swap contracts to manage its targeted mix of fixed and floating rate debt, and these swaps are valued using observable benchmark rates (Level 2 valuation). The Company utilizes forward-starting interest rate swaps to mitigate the risk of variability in interest rate for future debt issuances and these swaps are valued using observable benchmark rates (Level 2 valuation). The Company utilizes foreign currency contracts, including forward and swap contracts, option contracts, local currency deposits and local currency borrowings to hedge portions of its foreign currency purchases, assets and liabilities arising in the normal course of business and the net investment in certain foreign subsidiaries. These contracts are valued using observable market rates (Level 2 valuation). Commodity futures contracts are utilized to hedge the purchases of raw materials used in production. These contracts are measured using quoted commodity exchange prices (Level 1 valuation). The duration of foreign currency and commodity contracts generally does not exceed 12 months.
22

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
The following table summarizes the fair value of the Company’s derivative instruments and other financial instruments which are carried at fair value in the Company’s Consolidated Balance Sheets at September 30, 2020 and December 31, 2019:

| Assets |  | Liabilities
| Account |  | Fair Value |  | Account |  | Fair Value
Designated derivative instruments |  |  | September 30, 2020 |  | December 31, 2019 |  |  |  | September 30, 2020 |  | December 31, 2019
Interest rate swap contracts | Other current assets |  | $ | — |  |  | $ | — |  |  | Other accruals |  | $ | — |  |  | $ | — |
Interest rate swap contracts | Other assets |  | 15 |  |  | 4 |  |  | Other liabilities |  | — |  |  | — |
Forward-starting interest rate swaps | Other current assets |  | — |  |  | — |  |  | Other accruals |  | — |  |  | — |
Forward-starting interest rate swaps | Other assets |  | — |  |  | — |  |  | Other liabilities |  | 4 |  |  | — |
Foreign currency contracts | Other current assets |  | 14 |  |  | 6 |  |  | Other accruals |  | 28 |  |  | 15 |
Foreign currency contracts | Other assets |  | — |  |  | — |  |  | Other liabilities |  | 29 |  |  | 14 |
Commodity contracts | Other current assets |  | 1 |  |  | — |  |  | Other accruals |  | — |  |  | — |
Total designated |  | $ | 30 |  |  | $ | 10 |  |  |  |  | $ | 61 |  |  | $ | 29 |
Other financial instruments |  |  |  |  |  |  |  |  |  |  |
Marketable securities | Other current assets |  | $ | 80 |  |  | $ | 23 |  |  |  |  |  |  |
Total other financial instruments |  |  | $ | 80 |  |  | $ | 23 |  |  |  |  |  |  |

23

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
The carrying amount of cash, cash equivalents, marketable securities, accounts receivable and short-term debt approximated fair value as of September 30, 2020 and December 31, 2019. The estimated fair value of the Company’s long-term debt, including the current portion, as of September 30, 2020 and December 31, 2019, was $8,070 and $8,056, respectively, and the related carrying value was $7,227 and $7,587, respectively. The estimated fair value of long-term debt was derived principally from quoted prices on the Company’s outstanding fixed-term notes (Level 2 valuation).
The following amounts were recorded on the Condensed Consolidated Balance Sheet related to the cumulative basis adjustment for fair value hedges as of:

| September 30, 2020 |  | December 31, 2019
Long-term debt: |  |  |
Carrying amount of hedged item | $ | 414 |  |  | $ | 403 |
Cumulative hedging adjustment included in the carrying amount | 15 |  |  | 4 |

The following tables present the notional values as of:

| September 30, 2020
| Foreign Currency Contracts |  | Foreign Currency Debt |  | Interest Rate Swaps |  | Forward-Starting Interest Rate Swaps |  | Commodity Contracts |  | Total
Fair Value Hedges | $ | 586 |  |  | $ | — |  |  | $ | 400 |  |  | $ | — |  |  | $ | — |  |  | $ | 986 |
Cash Flow Hedges | 797 |  |  | — |  |  | — |  |  | 300 |  |  | 16 |  |  | 1,113 |
Net Investment Hedges | 585 |  |  | 3,487 |  |  | — |  |  | — |  |  | — |  |  | 4,072 |

| December 31, 2019
| Foreign Currency Contracts |  | Foreign Currency Debt |  | Interest Rate Swaps |  | Forward-Starting Interest Rate Swaps |  | Commodity Contracts |  | Total
Fair Value Hedges | $ | 388 |  |  | $ | — |  |  | $ | 400 |  |  | $ | — |  |  | $ | — |  |  | $ | 788 |
Cash Flow Hedges | 761 |  |  | — |  |  | — |  |  | — |  |  | 20 |  |  | 781 |
Net Investment Hedges | 478 |  |  | 3,856 |  |  | — |  |  | — |  |  | — |  |  | 4,334 |

24

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
The following tables present the location and amount of gains (losses) recognized on the Company’s Condensed Consolidated Statements of Income:

| Three Months Ended September 30,
| 2020 |  | 2019
| Cost of sales |  | Selling, general and administrative expenses |  | Interest (income) expense, net |  | Cost of sales |  | Selling, general and administrative expenses |  | Interest (income) expense, net
Gain (loss) on hedges recognized in income: |  |  |  |  |  |  |  |  |  |  |
Interest rate swaps designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  |
Derivative instrument | $ | — |  |  | $ | — |  |  | $ | 2 |  |  | $ | — |  |  | $ | — |  |  | $ | (2) |
Hedged items | — |  |  | — |  |  | (2) |  |  | — |  |  | — |  |  | 2 |
Foreign currency contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  |
Derivative instrument | — |  |  | (10) |  |  | — |  |  | — |  |  | — |  |  | — |
Hedged items | — |  |  | 10 |  |  | — |  |  | — |  |  | — |  |  | — |
Foreign currency contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  |
Amount reclassified from OCI | (1) |  |  | — |  |  | — |  |  | 1 |  |  | — |  |  | — |
Commodity contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  |
Amount reclassified from OCI | (1) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total gain (loss) on hedges recognized in income | $ | (2) |  |  | $ | — |  |  | $ | — |  |  | $ | 1 |  |  | $ | — |  |  | $ | — |

| Nine Months Ended September 30,
| 2020 |  | 2019
| Cost of sales |  | Selling, general and administrative expenses |  | Interest (income) expense, net |  | Cost of sales |  | Selling, general and administrative expenses |  | Interest (income) expense, net
Gain (loss) on hedges recognized in income: |  |  |  |  |  |  |  |  |  |  |
Interest rate swaps designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  |
Derivative instrument | $ | — |  |  | $ | — |  |  | $ | (11) |  |  | $ | — |  |  | $ | — |  |  | $ | (15) |
Hedged items | — |  |  | — |  |  | 11 |  |  | — |  |  | — |  |  | 15 |
Foreign currency contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  |
Derivative instrument | — |  |  | 29 |  |  | — |  |  | — |  |  | 10 |  |  | — |
Hedged items | — |  |  | (29) |  |  | — |  |  | — |  |  | (10) |  |  | — |
Foreign currency contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  |
Amount reclassified from OCI | 6 |  |  | — |  |  | — |  |  | 5 |  |  | — |  |  | — |
Commodity contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  |
Amount reclassified from OCI | (2) |  |  | — |  |  | — |  |  | 1 |  |  | — |  |  | — |
Total gain (loss) on hedges recognized in income | $ | 4 |  |  | $ | — |  |  | $ | — |  |  | $ | 6 |  |  | $ | — |  |  | $ | — |

25

COLGATE-PALMOLIVE COMPANY
Notes to Condensed Consolidated Financial Statements (continued)
(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)
The following table presents the location and amount of unrealized gains (losses) included in OCI:

| Three Months Ended
September 30,
2020 |  | 2019
Foreign currency contracts designated as cash flow hedges: |  |  |
Gain (loss) recognized in OCI | $ | (7) |  |  | $ | 7 |
Forward-starting interest rate swaps designated as cash flow hedges: |  |  |
Gain (loss) recognized in OCI | 4 |  |  | — |
Commodity contracts designated as cash flow hedges: |  |  |
Gain (loss) recognized in OCI | 2 |  |  | (1) |
Foreign currency contracts designated as net investment hedges: |  |  |
Gain (loss) on instruments | (21) |  |  | 23 |
Gain (loss) on hedged items | 21 |  |  | (23) |
Foreign currency debt designated as net investment hedges: |  |  |
Gain (loss) on instruments | (171) |  |  | 100 |
Gain (loss) on hedged items | 171 |  |  | (100) |
Total unrealized gain (loss) on hedges recognized in OCI | $ | (1) |  |  | $ | 6 |

| Nine Months Ended
September 30,
2020 |  | 2019
Foreign currency contracts designated as cash flow hedges: |  |  |
Gain (loss) recognized in OCI | $ | 6 |  |  | $ | 2 |
Forward-starting interest rate swaps designated as cash flow hedges: |  |  |
Gain (loss) recognized in OCI | (4) |  |  | — |
Commodity contracts designated as cash flow hedges: |  |  |
Gain (loss) recognized in OCI | — |  |  | 1 |
Foreign currency contracts designated as net investment hedges: |  |  |
Gain (loss) on instruments | (8) |  |  | 22 |
Gain (loss) on hedged items | 8 |  |  | (22) |
Foreign currency debt designated as net investment hedges: |  |  |
Gain (loss) on instruments | (174) |  |  | 105 |
Gain (loss) on hedged items | 174 |  |  | (105) |
Total unrealized gain (loss) on hedges recognized in OCI | $ | 2 |  |  | $ | 3 |

26

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Executive Overview
Business Organization
Colgate-Palmolive Company (together with its subsidiaries, “we,” the “Company” or “Colgate”) is a caring, innovative growth company reimagining a healthier future for people, their pets and our planet. We seek to deliver strong, consistent business results and superior shareholder returns, as well as to provide Colgate people with an innovative and inclusive work environment. We do this by developing and selling products globally that make people’s lives healthier and more enjoyable and by embracing our sustainability, diversity, equity and inclusion and social responsibility strategy across our organization.
We are tightly focused on two product segments: Oral, Personal and Home Care; and Pet Nutrition. Within these segments, we follow a closely defined business strategy to grow our key product categories and increase our overall market share. Within the categories in which we compete, we prioritize our efforts based on their capacity to maximize the use of the organization’s core competencies and strong global equities and to deliver sustainable, profitable long-term growth.
Operationally, we are organized along geographic lines with management teams having responsibility for the business and financial results in each region. We compete in more than 200 countries and territories worldwide with established businesses in all regions contributing to our sales and profitability. Approximately 70% of our Net sales are generated from markets outside the U.S., with approximately 45% of our Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). This geographic diversity and balance help to reduce our exposure to business and other risks in any one country or part of the world.
The Oral, Personal and Home Care product segment is managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of traditional and eCommerce retailers, wholesalers and distributors. Through Hill’s Pet Nutrition, we also compete on a worldwide basis in the pet nutrition market, selling products principally through authorized pet supply retailers, veterinarians and eCommerce retailers. We are engaged in manufacturing and sourcing of products and materials on a global scale and have major manufacturing, warehousing facilities and distribution centers in every region around the world.
On an ongoing basis, management focuses on a variety of key indicators to monitor business health and performance. These indicators include net sales (including volume, pricing and foreign exchange components), organic sales growth (net sales growth excluding the impact of foreign exchange, acquisitions and divestments), a non-GAAP financial measure, and gross profit margin, operating profit, net income and earnings per share, in each case, on a GAAP and non-GAAP basis, as well as measures used to optimize the management of working capital, capital expenditures, cash flow and return on capital. In addition, we review market share data to assess how our brands are performing within their categories on a global and regional basis. The monitoring of these indicators and our Code of Conduct and corporate governance practices help to maintain business health and strong internal controls. For additional information regarding non-GAAP financial measures and the Company’s use of market share data and the limitations of such data, see “Non-GAAP Financial Measures” and “Market Share Information” below.
COVID-19
The COVID-19 pandemic and government steps to control the spread of COVID-19 have had and continue to have a profound impact on the way people live, work, interact and shop and have significantly impacted and may continue to impact economic activity around the world. We have a well-established Crisis Management Team (“CMT”) process, and the CMT, together with our senior management team and Colgate people around the world, continue to respond to and manage the challenges presented by COVID-19.
During the nine months ended September 30, 2020 many of the communities in which we manufacture, market and sell our products experienced unprecedented “stay at home” orders, travel or movement restrictions and other government actions to reduce the spread and address the impact of COVID-19, and have implemented varying policies to resume economic activity. The situation continues to be uncertain and varies by geography, as infection rates of COVID-19 continue to increase in many regions throughout the world, and authorities have taken different approaches to address the pandemic and resume economic activity. Because the vast majority of our products (such as oral care products, soaps and other personal hygiene products, home cleaners and pet food) have been deemed essential for the health and well-being of people and their pets, we have, in most instances, been able to continue operating our business.
27

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
In so doing, the health and safety of Colgate employees has been and remains our first priority. Many of our employees globally continued to work from home during the quarter ended September 30, 2020. In those instances where our employees cannot perform their work at home, such as in our factories and in certain of our laboratories, or in geographies where circumstances have allowed us to offer employees the ability to return to the office, often on a voluntary and staggered basis, we have implemented additional health and safety measures and social distancing protocols, consistent with government recommendations and/or requirements, to help to ensure their safety, often at an additional cost. In addition, during the nine months ended September 30, 2020, we have experienced some limited factory closures, particularly in India, and in some cases we have seen increased instances of absenteeism. In addition, some of our suppliers, customers, distributors and service providers have experienced disruptions to their businesses.
We saw a significant increase in demand across many of our categories in the nine months ended September 30, 2020, driven by consumer pantry-loading and increased consumption of our products. This was particularly true in certain categories, such as liquid hand soap, dish liquid, bar soap and cleaners, and we believe that some of the increase in demand in these categories is sustainable in light of changes in consumer behavior related to COVID-19. In other categories, such as oral care and pet food, consumer demand trends have continued to normalize in the quarter ended September 30, 2020. Across our business, changes in consumer demand for our products vary by product category and geography depending on, among other things, the severity of the COVID-19 outbreak and retailer availability. At the same time, during the nine months ended September 30, 2020, we continued to experience declines in certain channels, including professional sales and travel retail, due to the economic slowdown and restricted consumer movement in many geographies throughout the world. We also continue to see changes in the purchasing patterns of our consumers, including the nature and/or frequency of visits by consumers to retailers and dental, veterinary and skin health professionals and a shift in many markets to purchasing our products online. During the nine months ended September 30, 2020, in some instances, we were not able to keep up with the increased consumer demand for our products and our products were at times out of stock on retailers’ shelves. In some cases, we incurred additional costs as we worked to meet this increased demand. Despite continuing to significantly ramp up production of in-demand products, we expect that some of our products may continue to be out of stock on retailers’ shelves for a period of time.
Government actions in response to COVID-19 have impacted and may continue to impact our consumers’ ability to purchase and our ability to manufacture and distribute our products. While we believe that, in the long-term, consumer demand for the products in our categories will continue to be strong, uncertainties continue surrounding the timing and extent of the pandemic and its recovery. These uncertainties include: the impact of the timing and scale of changes to travel and movement restrictions in certain geographies, the availability and widespread distribution and use of a safe and effective COVID-19 vaccine, the timing and impact of consumer pantry-loading and destocking activity in certain markets, product demand trends and the impact of COVID-19 on the global economy. Our retail customers are also being impacted by the global pandemic; their success in addressing COVID-19 and maintaining their operations could impact consumer access to and sales of our products. We expect the ongoing economic impact and health concerns associated with COVID-19 to continue to impact consumer behavior, shopping patterns and consumption preferences despite the lifting of government restrictions and the reopening of economies around the world.
While we currently expect to be able to continue operating our business as described above and we intend to continue to work with government authorities and to follow the necessary protocols to maintain the health and safety of our employees and contract providers, uncertainty resulting from COVID-19 could result in an unforeseen additional disruption to our business, including our global supply chain and retailer network, and/or require us to incur additional operational costs.
For more information about the anticipated COVID-19 impact, see “Outlook” below.
28

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Business Strategy
To achieve our business and financial objectives, we are focused on innovating our core businesses; improving our brand building activities; innovating to gain market share in high growth segments and adjacencies; expanding into new channels and markets; maximizing growth online; and investing to drive consumption in growing populations. We continue to develop initiatives to build strong relationships with consumers, dental, veterinary and skin health professionals and traditional and eCommerce retailers. In addition, we continue to invest behind our brands, not just in terms of advertising, but also to build key growth capabilities in areas such as innovation and data and analytics. We also continue to broaden our eCommerce offerings, including direct-to-consumer and subscription services. We continue to believe that growth opportunities are greater in those areas of the world in which economic development and rising consumer incomes expand the size and number of markets for the Company’s products. We are also working to integrate our sustainability, diversity, equity and inclusion and social responsibility strategy across our organization.
We are also changing the way we work to drive growth and how we approach innovation to respond to the dynamic retail landscape and the evolving preferences of our customers and consumers. The retail landscape, the ease of new entrants into the market in many of our categories and the evolving preferences of our customers and consumers demand that we work differently and faster in an agile, authentic and culturally relevant manner to drive innovation.
The investments needed to drive growth are supported by strong cash flow performance and our disciplined capital allocation strategy. These investments are developed through continuous, Company-wide initiatives to lower costs and increase effective asset utilization. Through these initiatives, which are referred to as our funding-the-growth initiatives, we seek to become even more effective and efficient throughout our businesses. These initiatives are designed to reduce costs associated with direct materials, indirect expenses, distribution and logistics, and advertising and promotional materials, among other things, and encompass a wide range of projects, examples of which include raw material substitution, reduction of packaging materials, consolidating suppliers to leverage volumes and increasing manufacturing efficiency through SKU reductions and formulation simplification. We also continue to prioritize our investments in high growth segments within our Oral Care, Personal Care and Pet Nutrition businesses, including by expanding our portfolio in premium skin health.
Significant Items Impacting Comparability
On January 31, 2020, the Company acquired Hello Products LLC (“Hello”), an oral care business, for cash consideration of $351. The acquisition was financed with a combination of debt and cash. This acquisition is part of the Company’s strategy to focus on high growth segments within its Oral Care, Personal Care and Pet Nutrition businesses. See Note 4, Acquisitions to the Condensed Consolidated Financial Statements for additional information.
The provision for income taxes for the nine months ended September 30, 2020 includes $71 of income tax benefits recorded on a discrete period basis of which $45 relates to previously recorded foreign withholding taxes and $26 relates to a previously recorded valuation allowance against a deferred tax asset. As more fully described in “Results of Operations-Income Taxes,” and in Note 10, Income Taxes to the Condensed Consolidated Financial Statements, both items were previously recorded in connection with the charge recorded in 2017 and revised in 2018 related to the Tax Cuts and Jobs Act (the “TCJA”).
On September 19, 2019, the Company acquired Laboratoires Filorga Cosmétiques S.A. (“Filorga”), a skin health business, for cash consideration of €1,548 (approximately $1,712). Filorga is a premium anti-aging skin health brand focused primarily on facial care. The acquisition was financed with a combination of debt and cash. This acquisition is part of our strategy to focus on high growth segments within our Oral Care, Personal Care and Pet Nutrition businesses, including by expanding our portfolio in premium skin health. On July 17, 2020, the Company completed the purchase of the outstanding non-controlling interest of Filorga’s joint venture based in Hong Kong and covering the Hong Kong and China markets for approximately €85 (approximately $99) in cash. See Note 4, Acquisitions to the Condensed Consolidated Financial Statements for additional information.
29

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Our restructuring program, known as the “Global Growth and Efficiency Program,” concluded on December 31, 2019. The program’s initiatives were designed to help us ensure sustained solid worldwide growth in unit volume, organic sales, operating profit and earnings per share and to enhance our global leadership positions in our core businesses. During the three months ended September 30, 2020, the Company adjusted the accrual balances related to certain projects approved prior to the conclusion of the Global Growth and Efficiency Program to reflect its revised estimate of remaining liabilities. This adjustment resulted in a reduction of $16 ($13 after-tax) to restructuring accruals as of September 30, 2020. No new restructuring projects were approved for implementation during the nine months ended September 30, 2020. See Note 5, Restructuring and Related Implementation Charges to the Condensed Consolidated Financial Statements for additional information.
30

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Outlook
Looking forward, we expect global macroeconomic, political and market conditions to remain challenging, especially due to the COVID-19 pandemic. We have seen short-term improvement in category growth rates due to heightened demand for certain health and hygiene products, particularly liquid hand soap, dish liquid, bar soap and cleaners. While we believe some of this is sustainable due to consumer behavior changes resulting from the COVID-19 pandemic, we have seen increased volatility in consumption rates across all of our categories as a result of the pandemic and it is therefore difficult to predict category growth rates over the next six to twelve months. In the longer term, post COVID-19, we expect category growth rates to remain below historical levels, except for the categories discussed above and pet nutrition, where we expect consumption to remain elevated to some extent for the foreseeable future.
While the global marketplace in which we operate has always been highly competitive, we continue to experience heightened competitive activity in certain markets from strong local competitors, from other large multinational companies, some of which have greater resources than we do, and from new entrants into the market in many of our categories. Such activities have included more aggressive product claims and marketing challenges, as well as increased promotional spending and geographic expansion. We have seen increases in promotional activities in certain markets as retailers try aggressively to get consumers back into the stores after prolonged “stay at home” and other government restrictions ease, a trend we expect will continue. We have been negatively affected by changes in the policies or practices of our retail trade customers in key markets, such as inventory de-stocking, limitations on access to shelf space or delisting of our products. In addition, the retail landscape in many of our markets continues to be impacted by the rapid growth of eCommerce retailers, changing consumer preferences (as consumers increasingly shop online) and the emergence of alternative retail channels, such as subscription services and direct-to-consumer businesses. These trends have been magnified due to the COVID-19 pandemic in many of our geographies and we plan to continue to invest behind our eCommerce capabilities. This rapid growth in eCommerce and the emergence of alternative retail channels have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers. In addition, given that approximately 70% of our Net sales originate in markets outside the U.S., we have experienced and will likely continue to experience increasingly volatile foreign currency fluctuations and higher raw and packaging material costs. While we have taken, and will continue to take, measures to mitigate the effect of these conditions, in the current environment, it may become increasingly difficult to implement certain of these mitigation strategies. Should these conditions persist, they could adversely affect our future results.
As discussed above, we continue to closely monitor the impact of COVID-19 on our business. While we have taken, and will continue to take, measures to mitigate the effects of COVID-19, we cannot estimate with certainty the full extent of COVID-19’s impact on our business, results of operations, cash flows and/or financial condition. For more information about factors that could impact our business, including due to COVID-19, see “Risk Factors” in Part II, Item IA of this Quarterly Report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019.
In summary, we believe we are well prepared to meet the challenges ahead due to our strong financial condition, experience operating in challenging environments, resilient global supply chain and continued focus on our key priorities: growing sales through engaging with consumers, developing world-class innovation and working with retail partners; driving efficiency on every line of the income statement to increase margins; generating strong cash flow performance and utilizing that cash effectively to enhance total shareholder return; and leading to win by staying true to our culture and focusing on all of our stakeholders. Our key focus is to sustain the underlying momentum of our business, to adapt our financial plans to deliver on 2020, while leaving us well positioned for continued growth in 2021. Our commitment to these priorities, together with the strength of our global brands, our broad international presence in both developed and emerging markets and cost-saving initiatives, such as our funding-the-growth initiatives, should position us well to manage through the COVID-19 pandemic and to increase shareholder value over the long term.
31

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Results of Operations
Three Months
Worldwide Net sales were $4,153 in the third quarter of 2020, up 5.5% from the third quarter of 2019, as volume growth of 5.0% and net selling price increases of 4.5% were partially offset by negative foreign exchange of 4.0%. Acquisitions contributed 2% to volume. Organic sales (Net sales excluding the impact of foreign exchange, acquisitions and divestments), a non-GAAP financial measure, increased 7.5% in the third quarter of 2020. A reconciliation of net sales growth to organic sales growth is provided under “Non-GAAP Financial Measures” below.
Net sales in the Oral, Personal and Home Care product segment were $3,449 in the third quarter of 2020, up 4.5% from the third quarter of 2019, as volume growth of 4.5% and net selling price increases of 4.5% were partially offset by negative foreign exchange of 4.5%. Acquisitions contributed 2.5% to volume. Organic sales in the Oral, Personal and Home Care product segment increased 6.5% in the third quarter of 2020.
The Company’s share of the global toothpaste market was 39.9% on a year-to-date basis, down 0.8 share points from the year ago period, and its share of the global manual toothbrush market was 31.1% on a year-to-date basis, up 0.2 share points from the year ago period. Year-to-date market shares in toothpaste were up in North America and Latin America and down in Europe, Asia Pacific and Africa/Eurasia versus the comparable 2019 period. In the manual toothbrush category, year-to-date market shares were up in North America, Latin America, Europe and Africa/Eurasia and down in Asia Pacific versus the comparable 2019 period. For additional information regarding market shares, see “Market Share Information” below.
Net sales in the Hill’s Pet Nutrition segment were $704 in the third quarter of 2020, up 11.0% from the third quarter of 2019, due to volume growth of 6.5% and net selling price increases of 4.5% while foreign exchange was flat. Organic sales in the Hill’s Pet Nutrition segment increased 11.0% in the third quarter of 2020.
32

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Gross Profit/Margin
Worldwide Gross profit increased to $2,540 in the third quarter of 2020 from $2,316 in the third quarter of 2019. Gross profit in the third quarter of 2019 included charges resulting from the Global Growth and Efficiency Program. Excluding charges resulting from the Global Growth and Efficiency Program in the third quarter of 2019, Gross profit increased to $2,540 in the third quarter of 2020 from $2,317 in the third quarter of 2019, an increase of $134 resulting from higher Net sales and an increase of $89 resulting from higher Gross profit margin.
Worldwide Gross profit margin increased to 61.2% in the third quarter of 2020 from 59.0% in the third quarter of 2019. Excluding charges resulting from the Global Growth and Efficiency Program in the third quarter of 2019, Gross profit margin increased by 220 basis points (bps) to 61.2% in the third quarter of 2020 from 59.0% in the third quarter of 2019. This increase in Gross profit margin was primarily due to cost savings from the Company’s funding-the-growth initiatives (250 bps) and higher pricing (170 bps), partially offset by higher raw and packaging material costs (230 bps), which included foreign exchange transaction costs.

|  | Three Months Ended September 30,
|  | 2020 |  | 2019
Gross profit, GAAP |  | $ | 2,540 |  |  | $ | 2,316 |
Global Growth and Efficiency Program |  | — |  |  | 1 |
Gross profit, non-GAAP |  | $ | 2,540 |  |  | $ | 2,317 |

|  | Three Months Ended September 30,
|  | 2020 |  | 2019 |  | Basis Point Change
Gross profit margin, GAAP |  | 61.2 | % |  | 59.0 | % |  | 220 |
Global Growth and Efficiency Program |  | — |  |  | — |  |  |
Gross profit margin, non-GAAP |  | 61.2 | % |  | 59.0 | % |  | 220 |

33

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased 6% to $1,518 in the third quarter of 2020 from $1,429 in the third quarter of 2019. Selling, general and administrative expenses in the third quarter of 2020 included benefits resulting from the Global Growth and Efficiency Program and, in the third quarter of 2019, included charges resulting from the Global Growth and Efficiency Program. Excluding these items in both periods as applicable, Selling, general and administrative expenses increased to $1,521 in the third quarter of 2020 from $1,401 in the third quarter of 2019, reflecting higher overhead expenses of $67 and increased advertising investment of $53.
Selling, general and administrative expenses as a percentage of Net sales increased to 36.6% in the third quarter of 2020 from 36.4% in the third quarter of 2019. Excluding the items described above in both periods as applicable, Selling, general and administrative expenses as a percentage of Net sales increased by 90 bps to 36.6% in the third quarter of 2020 as compared to 35.7% in the third quarter of 2019. This increase was due to increased advertising investment (70 bps) and higher overhead expenses (20 bps), primarily driven by higher logistics costs, both as a percentage of Net sales. In the third quarter of 2020, advertising investment increased as a percentage of Net sales to 11.5% from 10.8% in the third quarter of 2019, or 13% in absolute terms to $476 as compared with $423 in the third quarter of 2019.

|  | Three Months Ended September 30,
|  | 2020 |  | 2019
Selling, general and administrative expenses, GAAP |  | $ | 1,518 |  |  | $ | 1,429 |
Global Growth and Efficiency Program |  | 3 |  |  | (28) |
Selling, general and administrative expenses, non-GAAP |  | $ | 1,521 |  |  | $ | 1,401 |

|  | Three Months Ended September 30,
|  | 2020 |  | 2019 |  | Basis Point Change
Selling, general and administrative expenses as a percentage of Net sales, GAAP |  | 36.6 | % |  | 36.4 | % |  | 20
Global Growth and Efficiency Program |  | — |  |  | (0.7) |  |  |
Selling, general and administrative expenses as a percentage of Net sales, non-GAAP |  | 36.6 | % |  | 35.7 | % |  | 90

34

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Operating Profit
Operating profit increased 19% to $1,018 in the third quarter of 2020 from $856 in the third quarter of 2019. Operating profit in the third quarter of 2020 included benefits resulting from the Global Growth and Efficiency Program. Operating profit in the third quarter of 2019 included charges resulting from the Global Growth and Efficiency Program and acquisition-related costs. Excluding these items in both periods as applicable, Operating profit increased to $1,002 in the third quarter of 2020 from $900 in the third quarter of 2019, as an increase in Gross profit was partially offset by an increase in Selling, general and administrative expenses.
Operating profit margin was 24.5% in the third quarter of 2020, an increase of 270 bps compared to 21.8% in the third quarter of 2019. Excluding the items described above in both periods as applicable, Operating profit margin was 24.1% in the third quarter of 2020, an increase of 120 bps compared to 22.9% in the third quarter of 2019. This increase in Operating profit margin was primarily due to an increase in Gross profit (220 bps), partially offset by an increase in Selling, general and administrative expenses (90 bps), both as a percentage of Net sales.

|  | Three Months Ended September 30,
|  | 2020 |  | 2019 |  | % Change
Operating profit, GAAP |  | $ | 1,018 |  |  | $ | 856 |  |  | 19 | %
Global Growth and Efficiency Program |  | (16) |  |  | 26 |  |  | — |
Acquisition-related costs |  | — |  |  | 18 |  |  | — |
Operating profit, non-GAAP |  | $ | 1,002 |  |  | $ | 900 |  |  | 11 | %

|  | Three Months Ended September 30,
|  | 2020 |  | 2019 |  | Basis Point Change
Operating profit margin, GAAP |  | 24.5 | % |  | 21.8 | % |  | 270 |
Global Growth and Efficiency Program |  | (0.4) |  |  | 0.7 |  |  | — |
Acquisition-related costs |  | — |  |  | 0.4 |  |  | — |
Operating profit margin, non-GAAP |  | 24.1 | % |  | 22.9 | % |  | 120 |

Non-Service Related Postretirement Costs
Non-service related postretirement costs were $15 in the third quarter of 2020, as compared to $27 in the third quarter of 2019. Non-service related postretirement costs in the third quarter of 2019 included charges resulting from the Global Growth and Efficiency Program. Excluding charges resulting from the Global Growth and Efficiency Program in the third quarter of 2019, Non-service related postretirement costs were $15 in the third quarter of 2020, as compared to $26 in the third quarter of 2019, primarily due to lower interest cost.

|  | Three Months Ended September 30,
|  | 2020 |  | 2019
Non-service related postretirement costs, GAAP |  | $ | 15 |  |  | $ | 27 |
Global Growth and Efficiency Program |  | — |  |  | (1) |
Non-service related postretirement costs, non-GAAP |  | $ | 15 |  |  | $ | 26 |

Interest (Income) Expense, Net
Interest (income) expense, net was $36 in the third quarter of 2020 as compared to $35 in the third quarter of 2019.
35

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Net Income Attributable to Colgate-Palmolive Company and Earnings Per Share
Net income attributable to Colgate-Palmolive Company in the third quarter of 2020 increased to $698 from $578 in the third quarter of 2019, and Earnings per common share on a diluted basis increased to $0.81 per share in the third quarter of 2020 from $0.67 in the third quarter of 2019. Net income attributable to Colgate-Palmolive Company in the third quarter of 2020 included benefits resulting from the Global Growth and Efficiency Program, and in the third quarter of 2019 included charges resulting from the Global Growth and Efficiency Program and acquisition-related costs.
Excluding the items described above in both periods as applicable, Net income attributable to Colgate-Palmolive Company in the third quarter of 2020 increased 12% to $685 from $614 in the third quarter of 2019, and Earnings per common share on a diluted basis increased 11% to $0.79 in the third quarter of 2020 from $0.71 in the third quarter of 2019.

| Three Months Ended September 30, 2020
| Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Net Income Including Noncontrolling Interests |  | Net Income Attributable To Colgate-Palmolive Company |  |  |  | Diluted Earnings Per Share(2)
As Reported GAAP | $ | 967 |  |  | $ | 222 |  |  | $ | 745 |  |  | $ | 698 |  |  |  |  | $ | 0.81 |
Global Growth and Efficiency Program | (16) |  |  | (3) |  |  | (13) |  |  | (13) |  |  |  |  | (0.02) |
Non-GAAP | $ | 951 |  |  | $ | 219 |  |  | $ | 732 |  |  | $ | 685 |  |  |  |  | $ | 0.79 |

| Three Months Ended September 30, 2019
| Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Net Income Including Noncontrolling Interests |  |  | Net Income Attributable To Colgate-Palmolive Company |  |  | Diluted Earnings Per Share(2)
As Reported GAAP | $ | 794 |  |  | $ | 167 |  |  | $ | 627 |  |  |  | $ | 578 |  |  |  | $ | 0.67 |
Global Growth and Efficiency Program | 27 |  |  | 5 |  |  | 22 |  |  |  | 22 |  |  |  | 0.03 |
Acquisition-related costs | 18 |  |  | 4 |  |  | 14 |  |  |  | 14 |  |  |  | 0.01 |
Non-GAAP | $ | 839 |  |  | $ | 176 |  |  | $ | 663 |  |  |  | $ | 614 |  |  |  | $ | 0.71 |

(1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
(2) The impact of non-GAAP adjustments on diluted earnings per share may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding.
36

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Net Sales and Operating Profit by Segment
Oral, Personal and Home Care
North America

| Three Months Ended September 30,
| 2020 |  | 2019 |  | Change
Net sales | $ | 923 |  |  | $ | 869 |  |  | 6.5 |  | %
Operating profit | $ | 242 |  |  | $ | 248 |  |  | (2) |  | %
% of Net sales | 26.2 | % |  | 28.5 | % |  | (230) |  | bps

Net sales in North America increased 6.5% in the third quarter of 2020 to $923 as a result of volume growth of 3.0% and net selling price increases of 3.5%, while foreign exchange was flat. The Company’s acquisition of Hello contributed 1.5% to volume in North America. Organic sales in North America increased 5.0% in the third quarter of 2020. Organic sales growth was led by the United States.
The increase in organic sales in North America in the third quarter of 2020 versus the third quarter of 2019 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the power toothbrush and toothpaste categories. The increase in Personal Care was primarily due to organic sales growth in the liquid hand soap category, partially offset by declines in organic sales in the skin health and underarm protection categories. The increase in Home Care was primarily due to organic sales growth in the hand dish category, partially offset by a decline in organic sales in the fabric softener category.
Operating profit in North America decreased 2% in the third quarter of 2020 to $242, or 230 bps to 26.2% as a percentage of Net sales. This decrease in Operating profit as a percentage of Net sales was due to increases in Selling, general and administrative expenses (340 bps) and Other (income) expense, net (150 bps), partially offset by an increase in Gross profit (260 bps), all as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (220 bps) and higher pricing, partially offset by higher raw and packaging material costs (70 bps). This increase in Selling, general and administrative expenses was due to higher overhead expenses (190 bps), primarily driven by higher logistics costs, and increased advertising investment (150 bps). The increase in Other (income) expense, net was primarily due to an inventory write off.
Latin America

| Three Months Ended September 30,
| 2020 |  | 2019 |  | Change
Net sales | $ | 837 |  |  | $ | 881 |  |  | (5.0) |  | %
Operating profit | $ | 250 |  |  | $ | 235 |  |  | 6 |  | %
% of Net sales | 29.9 | % |  | 26.7 | % |  | 320 |  | bps

Net sales in Latin America decreased 5.0% in the third quarter of 2020 to $837, as negative foreign exchange of 16.5% was partially offset by volume growth of 2.0% and net selling price increases of 9.5%. Organic sales in Latin America increased 11.5% in the third quarter of 2020. Organic sales growth was led by Brazil, Argentina, Mexico and Colombia.
The increase in organic sales in Latin America in the third quarter of 2020 versus the third quarter of 2019 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Personal Care was primarily due to organic sales growth in the bar soap, shampoo and liquid hand soap categories, partially offset by a decline in organic sales in the underarm protection category. The increase in Home Care was primarily due to organic sales growth in the hand dish, fabric softener and liquid cleaner categories.
37

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Operating profit in Latin America increased 6% in the third quarter of 2020 to $250, or 320 bps to 29.9% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (260 bps) and a decrease in Other (income) expense, net (50 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (410 bps) and higher pricing, partially offset by higher raw and packaging material costs (580 bps), which included foreign exchange transaction costs. This decrease in Other (income) expense, net was due to a value added tax matter in Brazil.
Europe

| Three Months Ended September 30,
| 2020 |  | 2019 |  | Change
Net sales | $ | 712 |  |  | $ | 607 |  |  | 17.0 |  | %
Operating profit | $ | 169 |  |  | $ | 153 |  |  | 10 |  | %
% of Net sales | 23.7 | % |  | 25.2 | % |  | (150) |  | bps

Net sales in Europe increased 17.0% in the third quarter of 2020 to $712 due to volume growth of 12.0%, an increase in net selling prices of 0.5% and positive foreign exchange of 4.5%. The Company’s acquisition of Filorga contributed 9.5% to volume in Europe. Organic sales in Europe increased 3.0% in the third quarter of 2020. Organic sales growth in France, the Netherlands and Denmark were partially offset by an organic sales decline in the United Kingdom.
The increase in organic sales in Europe in the third quarter of 2020 versus the third quarter of 2019 was primarily due to an increase in Personal Care and Home Care organic sales. The increase in Personal Care was primarily due to organic sales growth in the liquid hand soap and body wash categories, partially offset by a decline in organic sales in the underarm protection category. The increase in Home Care was primarily due to organic sales growth in the fabric softener and hand dish categories.
Operating profit in Europe increased 10% in the third quarter of 2020 to $169, while as a percentage of Net sales it decreased 150 bps to 23.7%. This decrease in Operating profit as a percentage of Net sales was due to increases in Selling, general and administrative expenses (330 bps) and Other (income) expense, net (80 bps), partially offset by an increase in Gross profit (260 bps), all as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (200 bps) and favorable mix (140 bps), partially offset by higher raw and packaging material costs (70 bps). This increase in Selling, general and administrative expenses was due to increased advertising investment (200 bps) and higher overhead expenses (130 bps). This increase in Other (income) expense, net was due to amortization expense related to the Filorga acquisition.
Asia Pacific

| Three Months Ended September 30,
| 2020 |  | 2019 |  | Change
Net sales | $ | 722 |  |  | $ | 690 |  |  | 4.5 |  | %
Operating profit | $ | 222 |  |  | $ | 193 |  |  | 15 |  | %
% of Net sales | 30.7 | % |  | 28.0 | % |  | 270 |  | bps

Net sales in Asia Pacific increased 4.5% in the third quarter of 2020 to $722 due to volume growth of 2.5% and selling price increases of 2.0%, while foreign exchange was flat. Organic sales in Asia Pacific increased 4.5% in the third quarter of 2020. Organic sales growth was led by Australia, India, the Philippines and the Greater China region.
The increase in organic sales in Asia Pacific in the third quarter of 2020 versus the third quarter of 2019 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to an increase in organic sales in the toothpaste category. The increase in Personal Care was primarily due to organic sales growth in the liquid hand soap and shampoo categories. The increase in Home Care was primarily due to organic sales growth in the hand dish category.
38

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Operating profit in Asia Pacific increased 15% in the third quarter of 2020 to $222, or 270 bps to 30.7% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (150 bps), and a decrease in Selling, general and administrative expenses (110 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (230 bps) and higher pricing, partially offset by higher raw and packaging material costs (140 bps). This decrease in Selling, general and administrative expenses was due to lower overhead expenses (80 bps) and decreased advertising investment (30 bps).
Africa/Eurasia

| Three Months Ended September 30,
| 2020 |  | 2019 |  | Change
Net sales | $ | 255 |  |  | $ | 248 |  |  | 2.5 |  | %
Operating profit | $ | 61 |  |  | $ | 48 |  |  | 27 |  | %
% of Net sales | 23.9 | % |  | 19.4 | % |  | 450 |  | bps

Net sales in Africa/Eurasia increased 2.5% in the third quarter of 2020 to $255, as volume growth of 6.5% and net selling price increases of 6.5% were partially offset by negative foreign exchange of 10.5%. The Company’s acquisition of a 51% controlling interest in Colgate Tolaram Pte. Ltd., a joint venture which owns the Nigeria-based Hypo Homecare Products Limited (the “Nigeria Joint Venture”), contributed 1.0% to volume in Africa/Eurasia. Organic sales in Africa/Eurasia increased 12.0% in the third quarter of 2020. Organic sales growth was led by Russia, South Africa and Turkey.
The increase in organic sales in Africa/Eurasia in the third quarter of 2020 versus the third quarter of 2019 was primarily due to increases in Oral Care and Personal Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Personal Care was primarily due to organic sales growth in the body wash, liquid hand soap and bar soap categories.
Operating profit in Africa/Eurasia increased 27% in the third quarter of 2020 to $61, or 450 bps to 23.9% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (50 bps) and a decrease in Selling, general and administrative expenses (390 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (290 bps) and higher pricing, partially offset by higher raw and packaging material costs (460 bps), which included foreign exchange transaction costs. This decrease in Selling, general and administrative expenses was due to lower overhead expenses (240 bps) and decreased advertising investment (150 bps).
39

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Hill’s Pet Nutrition

| Three Months Ended September 30,
| 2020 |  | 2019 |  | Change
Net sales | $ | 704 |  |  | $ | 633 |  |  | 11.0 |  | %
Operating profit | $ | 196 |  |  | $ | 169 |  |  | 16 |  | %
% of Net sales | 27.8 | % |  | 26.7 | % |  | 110 |  | bps

Net sales for Hill’s Pet Nutrition increased 11.0% in the third quarter of 2020 to $704 due to volume growth of 6.5% and net selling price increases of 4.5%, while foreign exchange was flat. Organic sales in Hill’s Pet Nutrition increased 11.0% in the third quarter of 2020. Organic sales growth was led by the United States, Europe, Australia and Canada.
The increase in organic sales in the third quarter of 2020 was primarily due to organic sales growth in the Science Diet and Prescription Diet categories.
Operating profit in Hill’s Pet Nutrition increased 16% in the third quarter of 2020 to $196, or 110 bps to 27.8% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was due to an increase in Gross profit (140 bps), partially offset by an increase in Selling, general and administrative expenses (40 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to cost savings from the Company’s funding-the-growth initiatives (160 bps) and higher pricing, partially offset by higher raw and packaging material costs (130 bps). This increase in Selling, general and administrative expenses was due to increased advertising investment (220 bps), partially offset by lower overhead expenses (180 bps).
During the quarter ended March 31, 2019, Hill’s announced a voluntary recall, which was subsequently expanded, of select canned dog food products due to potentially elevated levels of Vitamin D resulting from a supplier error. In the United States, the voluntary recall was conducted in cooperation with the U.S. Food and Drug Administration. Following the announcement of the voluntary recall, and as of September 30, 2020, Hill’s and/or the Company have been named as defendants in 37 putative class action lawsuits, one putative class action filed on behalf of a European Union class and one individual action, all related to the voluntary recall and filed in various jurisdictions in the United States. In addition, two putative class actions related to the voluntary recall have been filed in Canada. Eight of the putative class actions lawsuits in the United States and one of the putative class action lawsuits in Canada have been voluntarily dismissed. Hill’s is entitled to indemnification from the supplier related to the voluntary recall. Sales of products voluntarily recalled represent less than 2% of Hill’s annual Net sales. The sales loss and other costs associated with the voluntary recall and subsequent expansion did not have a material impact on the Company’s Net sales or Operating profit and are not expected to have a material impact in future periods.
Corporate

| Three Months Ended September 30,
| 2020 |  | 2019 |  | Change |
Operating profit (loss) | $ | (122) |  |  | $ | (190) |  |  | (36) |  | %

Operating profit (loss) related to Corporate was ($122) in the third quarter of 2020 as compared to ($190) in the third quarter of 2019. In the third quarter of 2020, Corporate Operating profit (loss) included benefits of $16 resulting from the Global Growth and Efficiency Program. In the third quarter of 2019, Corporate Operating profit (loss) included charges of $26 resulting from the Global Growth and Efficiency Program and acquisition-related costs of $18.
40

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Nine Months
Worldwide Net sales were $12,147 in the first nine months of 2020, up 4.0% as compared to the first nine months of 2019, as volume growth of 5.5% and net selling price increases of 3.0% were partially offset by negative foreign exchange of 4.5%. Acquisitions contributed 2.0% to volume. Organic sales increased 6.5% in the first nine months of 2020.
Net sales in the Oral, Personal and Home Care product segment were $10,052 in the first nine months of 2020, an increase of 2.0% as compared to the first nine months of 2019, as volume growth of 4.5% and net selling price increases of 3.0% were partially offset by negative foreign exchange of 5.5%. Acquisitions contributed 2.0% to volume. Organic sales in the Oral, Personal and Home Care product segment increased 5.5% in the first nine months of 2020.
The increase in organic sales in the first nine months of 2020 versus the first nine months of 2019 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste category. The increase in Personal Care was primarily due to organic sales growth in the liquid hand soap, bar soap and body wash categories, partially offset by a decline in organic sales in the underarm protection category. The increase in Home Care was primarily due to organic sales growth in the hand dish and liquid cleaner categories.
Net sales in the Hill’s Pet Nutrition segment were $2,095 in the first nine months of 2020, an increase of 13.5% from the first nine months of 2019, as volume growth of 10.0% and net selling price increases of 4.5% were partially offset by negative foreign exchange of 1.0%. Organic sales in the Hill’s Pet Nutrition segment increased 14.5% in the first nine months of 2020.
41

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Net Sales and Operating Profit by Segment
Net sales and Operating profit by segment were as follows:

| Nine Months Ended September 30,
| 2020 |  | 2019
Net sales |  |  |
Oral, Personal and Home Care |  |  |
North America | $ | 2,801 |  |  | $ | 2,568 |
Latin America | 2,531 |  |  | 2,700 |
Europe | 2,004 |  |  | 1,798 |
Asia Pacific | 1,980 |  |  | 2,035 |
Africa/Eurasia | 736 |  |  | 732 |
Total Oral, Personal and Home Care | 10,052 |  |  | 9,833 |
Pet Nutrition | 2,095 |  |  | 1,845 |
Total Net sales | $ | 12,147 |  |  | $ | 11,678 |
Operating profit |  |  |
Oral, Personal and Home Care |  |  |
North America | $ | 753 |  |  | $ | 750 |
Latin America | 728 |  |  | 718 |
Europe | 482 |  |  | 452 |
Asia Pacific | 559 |  |  | 557 |
Africa/Eurasia | 174 |  |  | 141 |
Total Oral, Personal and Home Care | 2,696 |  |  | 2,618 |
Pet Nutrition | 588 |  |  | 501 |
Corporate | (368) |  |  | (496) |
Total Operating profit | $ | 2,916 |  |  | $ | 2,623 |

Within the Oral, Personal and Home Care product segment, North America Net sales increased 9.0%, driven by volume growth of 8.5% and net selling price increases of 1.0%, partially offset by negative foreign exchange of 0.5%. The Hello acquisition contributed 1.5% to volume in North America. Organic sales in North America increased 8.0%. Latin America Net sales decreased 6.0%, driven by negative foreign exchange of 14.5%, partially offset by volume growth of 0.5% and net selling price increases of 8.0%. Organic sales in Latin America increased 8.5%. Europe Net sales increased 11.5%, driven by volume growth of 12.0%, partially offset by net selling prices decreases of 0.5% while foreign exchange was flat. The Filorga acquisition contributed 9.0% to volume in Europe. Organic sales in Europe increased 2.5%. Asia Pacific Net sales decreased 2.5%, driven by volume declines of 3.0% and negative foreign exchange of 1.5%, partially offset by net selling prices increases of 2.0%. Organic sales in Asia Pacific decreased 1.0%. Africa/Eurasia Net sales increased 0.5%, as volume growth of 5.5% and net selling price increases of 3.5% were partially offset by negative foreign exchange of 8.5%. The Nigeria Joint Venture contributed 1.5% to volume in Africa/Eurasia. Organic sales in Africa/Eurasia increased 7.5%.
In the first nine months of 2020, Operating profit (loss) related to Corporate was ($368) as compared to ($496) in the first nine months of 2019. In the first nine months of 2020, Corporate Operating profit (loss) included acquisition-related costs of $6 and benefits of $16 resulting from the Global Growth and Efficiency Program. In the first nine months of 2019, Corporate Operating profit (loss) included $94 of charges resulting from the Global Growth and Efficiency Program and acquisition-related costs of $18.
42

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Gross Profit/Margin
Worldwide Gross profit increased to $7,374 in the first nine months of 2020 from $6,911 in the first nine months of 2019. Gross profit in the first nine months of 2020 included acquisition-related costs. Gross profit in the first nine months of 2019 included charges resulting from the Global Growth and Efficiency Program. Excluding these items in both periods as applicable, Gross profit increased to $7,378 in the first nine months of 2020 from $6,920 in the first nine months of 2019, reflecting an increase of $287 resulting from higher Net sales and an increase of $171 resulting from higher Gross profit margin.
Worldwide Gross profit margin increased to 60.7% in the first nine months of 2020 from 59.2% in the first nine months of 2019. Excluding the items described above in both periods as applicable, Gross profit margin increased by 140 bps to 60.7% in the first nine months of 2020, from 59.3% in the first nine months of 2019, due to cost savings from the Company’s funding-the-growth initiatives (210 bps) and higher pricing (120 bps), partially offset by higher raw and packaging material costs (190 bps), which included foreign exchange transaction costs.

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019
Gross profit, GAAP |  | $ | 7,374 |  |  | $ | 6,911 |
Acquisition-related costs |  | 4 |  |  | — |
Global Growth and Efficiency Program |  | — |  |  | 9 |
Gross profit, non-GAAP |  | $ | 7,378 |  |  | $ | 6,920 |

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019 |  | Basis Point Change
Gross profit margin, GAAP |  | 60.7 | % |  | 59.2 | % |  | 150 |
Acquisition-related costs |  | — |  |  | — |  |  |
Global Growth and Efficiency Program |  | — |  |  | 0.1 |  |  |
Gross profit margin, non-GAAP |  | 60.7 | % |  | 59.3 | % |  | 140 |

43

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased 5% to $4,386 in the first nine months of 2020 from $4,163 in the first nine months of 2019. Selling, general and administrative expenses in the first nine months of 2020 included benefits resulting from the Global Growth and Efficiency Program. Selling, general and administrative expenses in the first nine months of 2019 included charges resulting from the Global Growth and Efficiency Program. Excluding these items in both periods as applicable, Selling, general and administrative expenses increased to $4,389 in the first nine months of 2020 from $4,121 in the first nine months of 2019, reflecting higher overhead expenses of $137 and increased advertising investment of $131.
Selling, general and administrative expenses as a percentage of Net sales increased to 36.1% in the first nine months of 2020 from 35.6% in the first nine months of 2019. Excluding the items described above in both periods as applicable, Selling, general and administrative expenses as a percentage of Net sales increased by 80 bps to 36.1% in the first nine months of 2020 as compared to 35.3% in the first nine months of 2019. This increase was due to increased advertising investment (60 bps) and higher overhead expenses (20 bps), both as a percentage of Net sales. In the first nine months of 2020, advertising investment increased as a percentage of Net sales to 11.5% from 10.9% in the first nine months of 2019, or 10.3% in absolute terms to $1,399, as compared with $1,268 in the first nine months of 2019.

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019
Selling, general and administrative expenses, GAAP |  | $ | 4,386 |  |  | $ | 4,163 |
Global Growth and Efficiency Program |  | 3 |  |  | (42) |
Selling, general and administrative expenses, non-GAAP |  | $ | 4,389 |  |  | $ | 4,121 |

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019 |  | Basis Point Change
Selling, general and administrative expenses as a percentage of Net sales, GAAP |  | 36.1 | % |  | 35.6 | % |  | 50
Global Growth and Efficiency Program |  | — |  |  | (0.3) |  |  |
Selling, general and administrative expenses as a percentage of Net sales, non-GAAP |  | 36.1 | % |  | 35.3 | % |  | 80

44

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Operating Profit
Operating profit increased 11% to $2,916 in the first nine months of 2020 from $2,623 in the first nine months of 2019. Operating profit in the first nine months of 2020 included acquisition-related costs and benefits resulting from the Global Growth and Efficiency Program. Operating profit in the first nine months of 2019 included charges resulting from the Global Growth and Efficiency Program and acquisitions-related costs. Excluding these items in both periods as applicable, Operating profit increased to $2,906 in the first nine months of 2020 from $2,735 in the first nine months of 2019, primarily due to an increase in Gross profit, partially offset by an increase in Selling, general and administrative expenses.
Operating profit margin was 24.0% in the first nine months of 2020, an increase of 150 bps compared to 22.5% in the first nine months of 2019. Excluding the items described above in both periods as applicable, Operating profit margin was 23.9% in the first nine months of 2020, an increase of 50 bps compared to 23.4% in the first nine months of 2019, as higher Gross profit (140 bps) was partially offset by an increase in Selling, general and administrative expenses (80 bps), both as a percentage of Net sales.

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019 |  | % Change
Operating profit, GAAP |  | $ | 2,916 |  |  | $ | 2,623 |  |  | 11 | %
Global Growth and Efficiency Program |  | (16) |  |  | 94 |  |  |
Acquisition-related costs |  | 6 |  |  | 18 |  |  |
Operating profit, non-GAAP |  | $ | 2,906 |  |  | $ | 2,735 |  |  | 6 | %

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019 |  | Basis Point Change
Operating profit margin, GAAP |  | 24.0 | % |  | 22.5 | % |  | 150
Global Growth and Efficiency Program |  | (0.1) |  |  | 0.8 |  |  |
Acquisition-related costs |  | — |  |  | 0.1 |  |  |
Operating profit margin, non-GAAP |  | 23.9 | % |  | 23.4 | % |  | 50

Non-Service Related Postretirement Costs
Non-service related postretirement costs were $56 in the first nine months of 2020, as compared to $79 in the first nine months of 2019. Non-service related postretirement costs in the first nine months of 2019 included charges resulting from the Global Growth and Efficiency Program. Excluding chargers resulting from the Global Growth and Efficiency Program in the first nine months of 2019, Non-service related postretirement costs were $56 in the first nine months of 2020, as compared to $75 in the first nine months of 2019, primarily due to lower interest cost.

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019
Non-service related postretirement costs, GAAP |  | $ | 56 |  |  | $ | 79 |
Global Growth and Efficiency Program |  | — |  |  | (4) |
Non-service related postretirement costs, non-GAAP |  | $ | 56 |  |  | $ | 75 |

Interest (Income) Expense, Net
Interest (income) expense, net was $107 in the first nine months of 2020 as compared to $113 in the first nine months of 2019, primarily due to lower average interest rates on debt.
45

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Income Taxes
The effective income tax rate was 23.0% for the third quarter of 2020 as compared to 21.0% for the third quarter of 2019. As reflected in the table below, the non-GAAP effective income tax rate was 23.0% for the quarter ended September 30, 2020, as compared to 21.0% in the comparable period of 2019.
The effective income tax rate was 21.2% for the first nine months of 2020 as compared to 24.1% for the first nine months of 2019. As reflected in the table below, the non-GAAP effective income tax rate was 23.9% for the first nine months of 2020, as compared to 24.1% in the comparable period of 2019.
The quarterly provision for income taxes is determined based on the Company’s estimated full year effective income tax rate adjusted by the amount of tax attributable to infrequent or unusual items that are separately recognized on a discrete basis in the income tax provision in the quarter in which they occur. The Company’s current estimate of its full year effective income tax rate before discrete period items is 24.0%, compared to 24.3% in the third quarter of 2019. See Note 10, Income Taxes to the Condensed Consolidated Financial Statements for additional details.

|  | Three Months Ended September 30,
|  | 2020 |  | 2019
|  | Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Effective Income Tax Rate(2) |  | Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Effective Income Tax Rate(2)
As Reported GAAP |  | $ | 967 |  |  | $ | 222 |  |  | 23.0 | % |  | $ | 794 |  |  | $ | 167 |  |  | 21.0 | %
Global Growth and Efficiency Program |  | (16) |  |  | (3) |  |  | — |  |  | 27 |  |  | 5 |  |  | (0.1) |
Acquisition-related costs |  | — |  |  | — |  |  | — |  |  | 18 |  |  | 4 |  |  | 0.1 | %
Non-GAAP |  | $ | 951 |  |  | $ | 219 |  |  | 23.0 | % |  | $ | 839 |  |  | $ | 176 |  |  | 21.0 | %

|  | Nine Months Ended September 30,
|  | 2020 |  | 2019
|  | Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Effective Income Tax Rate(2) |  | Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Effective Income Tax Rate(2)
As Reported GAAP |  | $ | 2,753 |  |  | $ | 585 |  |  | 21.2 | % |  | $ | 2,431 |  |  | $ | 586 |  |  | 24.1 | %
Global Growth and Efficiency Program |  | (16) |  |  | (3) |  |  | — |  |  | 98 |  |  | 23 |  |  | — |
Subsidiary and operating structure initiatives |  | — |  |  | 71 |  |  | 2.7 |  |  | — |  |  | — |  |  | — |
Acquisition-related costs |  | 6 |  |  | 2 |  |  | — |  |  | 18 |  |  | 4 |  |  | — |
Non-GAAP |  | $ | 2,743 |  |  | $ | 655 |  |  | 23.9 | % |  | $ | 2,547 |  |  | $ | 613 |  |  | 24.1 | %

(1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
(2) The impact of non-GAAP items on the Company’s effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes.
The provision for income taxes for the nine months ended September 30, 2020 includes $71 of income tax benefits recorded on a discrete period basis, of which $45 relates to previously recorded foreign withholding taxes and $26 relates to a previously recorded valuation allowance against a deferred tax asset. As more fully described below, both items were previously recorded in connection with the charge recorded by the Company in 2017 and revised in 2018 related to the TCJA.
46

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
As part of the previously recorded charge for the TCJA, the Company had provided for foreign withholding taxes expected to be paid on the remittance of earnings from certain overseas subsidiaries no longer deemed indefinitely reinvested. As a result of a recent reorganization of the ownership structure of certain foreign subsidiaries, the Company determined that no withholding taxes will be due on the remittance by certain subsidiaries of earnings previously deemed reinvested and, accordingly, reversed $45 of previously recorded foreign withholding taxes in the first quarter of 2020.
Also as part of the previously recorded charge for the TCJA, the Company provided a valuation allowance against a deferred tax asset related to foreign tax credit carry-forwards that the Company did not expect to be able to use due to changes made by the TCJA. As a result of a new operating structure being implemented within one of the Company’s divisions, the Company believes the use of these foreign tax credit carry-forwards will not be limited in the future and, accordingly, reversed the previously recorded valuation allowance of $26 in the first quarter of 2020.
47

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Net Income Attributable to Colgate-Palmolive Company and Earnings Per Share
Net income attributable to Colgate-Palmolive Company in the first nine months of 2020 increased to $2,048 from $1,724 in the comparable 2019 period. Earnings per common share on a diluted basis increased to $2.38 per share from $2.00 per share in the comparable 2019 period. Net income attributable to Colgate-Palmolive Company in the first nine months of 2020 included benefits resulting from the Global Growth and Efficiency Program, acquisition-related costs and a benefit related to subsidiary and operating structure initiatives. Net income attributable to Colgate-Palmolive Company in the comparable 2019 period included charges resulting from the Global Growth and Efficiency Program and acquisition-related costs.
Excluding the items described above in both periods as applicable, Net income attributable to Colgate-Palmolive Company in the first nine months of 2020 increased 9% to $1,968 from $1,813 in the first nine months of 2019, and Earnings per common share on a diluted basis increased 9% to $2.29 in the first nine months of 2020 from $2.10 in the first nine months of 2019.

| Nine Months Ended September 30, 2020
| Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Net Income Including Noncontrolling Interests |  | Net Income Attributable To Colgate-Palmolive Company |  |  |  | Diluted Earnings Per Share(2)
As Reported GAAP | $ | 2,753 |  |  | $ | 585 |  |  | $ | 2,168 |  |  | $ | 2,048 |  |  |  |  | $ | 2.38 |
Global Growth and Efficiency Program | (16) |  |  | (3) |  |  | (13) |  |  | (13) |  |  |  |  | (0.02) |
Subsidiary and operating structure initiatives | — |  |  | 71 |  |  | (71) |  |  | (71) |  |  |  |  | (0.08) |
Acquisition-related costs | 6 |  |  | 2 |  |  | 4 |  |  | 4 |  |  |  |  | 0.01 |
Non-GAAP | $ | 2,743 |  |  | $ | 655 |  |  | $ | 2,088 |  |  | $ | 1,968 |  |  |  |  | $ | 2.29 |

| Nine Months Ended September 30, 2019
| Income Before Income Taxes |  | Provision For Income Taxes(1) |  | Net Income Including Noncontrolling Interests |  |  | Net Income Attributable To Colgate-Palmolive Company |  |  | Diluted Earnings Per Share(2)
As Reported GAAP | $ | 2,431 |  |  | $ | 586 |  |  | $ | 1,845 |  |  |  | $ | 1,724 |  |  |  | $ | 2.00 |
Global Growth and Efficiency Program | 98 |  |  | 23 |  |  | 75 |  |  |  | 75 |  |  |  | 0.09 |
Acquisition-related costs | 18 |  |  | 4 |  |  | 14 |  |  |  | 14 |  |  |  | 0.01 |
Non-GAAP | $ | 2,547 |  |  | $ | 613 |  |  | $ | 1,934 |  |  |  | $ | 1,813 |  |  |  | $ | 2.10 |

(1) The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
(2) The impact of non-GAAP adjustments on diluted earnings per share may not necessarily equal the difference between “GAAP” and “non-GAAP” as a result of rounding.
48

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Non-GAAP Financial Measures
This Quarterly Report on Form 10-Q discusses certain financial measures on both a GAAP and a non-GAAP basis. The Company uses the non-GAAP financial measures described below internally in its budgeting process, to evaluate segment and overall operating performance and as a factor in determining compensation. The Company believes that these non-GAAP financial measures are useful in evaluating the Company’s underlying business performance and trends; however, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similar measures presented by other companies.
Net sales growth (GAAP) and organic sales growth (Net sales growth excluding the impact of foreign exchange, acquisitions and divestments) (non-GAAP) are discussed in this Quarterly Report on Form 10-Q. Management believes the organic sales growth measure provides investors and analysts with useful supplemental information regarding the Company’s underlying sales trends by presenting sales growth excluding the external factor of foreign exchange, as well as the impact of acquisitions and divestments, as applicable. A reconciliation of organic sales growth to Net sales growth for the three and nine months ended September 30, 2020 is provided below.
Worldwide Gross profit, Gross profit margin, Selling, general and administrative expenses, Selling, general and administrative expenses as a percentage of Net sales, Other (income) expense, net, Operating profit, Operating profit margin, Non-service related postretirement costs, effective income tax rate, Net income attributable to Colgate-Palmolive Company and Earnings per share on a diluted basis are discussed in this Quarterly Report on Form 10-Q both on a GAAP basis and excluding, as applicable, the benefits and charges resulting from the Global Growth and Efficiency Program, the charge related to U.S. tax reform, acquisition-related costs, and a benefit related to a recent reorganization of the ownership structure of certain foreign subsidiaries and a new operating structure being implemented within one of the Company’s divisions. These non-GAAP financial measures exclude items that, either by their nature or amount, management would not expect to occur as part of the Company’s normal business on a regular basis, such as restructuring charges, charges for certain litigation and tax matters, gains and losses from certain acquisition, divestitures and certain unusual, non-recurring items. Investors and analysts use these financial measures in assessing the Company’s business performance and management believes that presenting these financial measures on a non-GAAP basis provides them with useful supplemental information to enhance their understanding of the Company’s underlying business performance and trends. These non-GAAP financial measures also enhance the ability to compare period-to-period financial results. A reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measures for the three and nine months ended September 30, 2020 and 2019 is presented within the applicable section of Results of Operations.
The following tables provide a quantitative reconciliation of Net sales growth to organic sales growth for the three and nine months ended September 30, 2020:

Three Months Ended September 30, 2020 | Net Sales Growth (GAAP) | Foreign Exchange Impact | Acquisitions and Divestments Impact | Organic Sales Growth (Non-GAAP)
Oral, Personal and Home Care |  |  |  |
North America | 6.5% | —% | 1.5% | 5.0%
Latin America | (5.0)% | (16.5)% | —% | 11.5%
Europe | 17.0% | 4.5% | 9.5% | 3.0%
Asia Pacific | 4.5% | —% | —% | 4.5%
Africa/Eurasia | 2.5% | (10.5)% | 1.0% | 12.0%
Total Oral, Personal and Home Care | 4.5% | (4.5)% | 2.5% | 6.5%
Pet Nutrition | 11.0% | —% | —% | 11.0%
Total Company | 5.5% | (4.0)% | 2.0% | 7.5%

49

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)

Nine Months Ended September 30, 2020 | Net Sales Growth (GAAP) | Foreign Exchange Impact | Acquisitions and Divestments Impact | Organic Sales Growth (Non-GAAP)
Oral, Personal and Home Care |  |  |  |
North America | 9.0% | (0.5)% | 1.5% | 8.0%
Latin America | (6.0)% | (14.5)% | —% | 8.5%
Europe | 11.5% | —% | 9.0% | 2.5%
Asia Pacific | (2.5)% | (1.5)% | —% | (1.0)%
Africa/Eurasia | 0.5% | (8.5)% | 1.5% | 7.5%
Total Oral, Personal and Home Care | 2.0% | (5.5)% | 2.0% | 5.5%
Pet Nutrition | 13.5% | (1.0)% | —% | 14.5%
Total Company | 4.0% | (4.5)% | 2.0% | 6.5%

50

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Liquidity and Capital Resources
The Company expects cash flow from operations and debt issuances will be sufficient to meet foreseeable business operating and recurring cash needs (including for debt service, dividends, capital expenditures and stock repurchases). The Company believes its strong cash generation and financial position should continue to allow it broad access to global credit and capital markets.
Net cash provided by operations increased 27% to $2,756 in the first nine months of 2020, compared with $2,163 in the comparable period of 2019, primarily due to higher net income, improved working capital, lower voluntary contributions to the Company’s pension plans and lower income tax payments due to timing. The Company continues to be tightly focused on working capital. The Company’s working capital was (5.7%) as a percentage of Net sales in the first nine months of 2020 as compared to (2.8%) in the first nine months of 2019. The Company defines working capital as the difference between current assets (excluding Cash and cash equivalents and marketable securities, the latter of which is reported in Other current assets) and current liabilities (excluding short-term debt).
Investing activities used $668 of cash in the first nine months of 2020, compared with $2,075 in the comparable period of 2019. As more fully described below, investing activities in the first nine months of 2020 included the Company’s acquisition of Hello.
On January 31, 2020, the Company acquired Hello for cash consideration of $351. On September 19, 2019, the Company acquired Filorga for cash consideration of €1,516 (approximately $1,674) plus additional consideration of €32 (approximately $38), the majority of which related to repayment of loans from former shareholders of Filorga. On August 15, 2019, the Company acquired a 51% controlling interest in the Nigeria Joint Venture for $31.
These acquisitions were financed with a combination of debt and cash. As a result of the incremental debt related to these acquisitions, in accordance with the Company’s previously announced intention to moderate share repurchases into 2021, the Company continued to moderate its share repurchases in the first nine months of 2020. In addition, due to the uncertainties resulting from the COVID-19 pandemic, the Company discontinued all share repurchases other than those pursuant to equity plans during the second quarter of 2020. The Company resumed its moderated share repurchases in the third quarter of 2020.
Capital spending was $249 in the first nine months of 2020 compared to $226 in the comparable period of 2019. Capital expenditures for 2020 are expected to be approximately 2.0% to 2.5% of Net sales. The Company continues to focus its capital spending on projects that are expected to yield high aftertax returns.
Financing activities used $1,968 of cash during the first nine months of 2020, compared with $150 generated in the comparable period of 2019. This reflects net repayments on debt in the first nine months of 2020 compared with net proceeds on debt in the comparable period of 2019. This use of cash, as discussed above, was partially offset by lower share repurchases associated with the share repurchase program in the first nine months of 2020 compared with the comparable period of 2019.
On July 17, 2020, the Company completed the purchase of the outstanding non-controlling interest of Filorga’s joint venture based in Hong Kong and covering the Hong Kong and China markets for approximately €85 (approximately $99) in cash.
Long-term debt, including the current portion, decreased to $7,227 as of September 30, 2020, as compared to $7,587 as of December 31, 2019, and total debt was $7,236 as of September 30, 2020, as compared to $7,847 as of December 31, 2019. During the first quarter of 2019, the Company issued €500 of seven-year notes at a fixed coupon rate of 0.500% and €500 of fifteen-year notes at a fixed coupon rate of 1.375%. The debt issuances were under the Company’s shelf registration statement. The debt issuances support the Company’s capital structure objectives of funding its business and growth initiatives while minimizing its risk-adjusted cost of capital. Proceeds from the debt issuances were used for general corporate purposes, which included the retirement of commercial paper, and the repayment of the Company’s $500 1.75% fixed rate notes, which became due in March 2019, and €500 floating rate notes, which became due in May 2019.
51

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Domestic and foreign commercial paper outstanding was $91 and $2,275 as of September 30, 2020 and 2019, respectively. The average daily balances outstanding for commercial paper in the first nine months of 2020 and 2019 were $1,110 and $1,670, respectively. The Company classifies commercial paper and certain current maturities of notes payable as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis, including, if necessary, by utilizing its unused lines of credit of approximately $4,500 (including under the facilities discussed below) or by issuing long-term debt pursuant to an effective shelf registration statement. In November 2018, the Company entered into an amended and restated $2,650 revolving credit facility with a syndicate of banks that was scheduled to expire in November 2023. In August 2019, the term of the facility was extended by one year and it now expires in November 2024. In August 2020, the Company entered into a $1,500 364-day credit facility with a syndicate of banks that is scheduled to expire in August 2021. Commitment fees related to the credit facilities are not material.
Certain of the agreements with respect to the Company’s bank borrowings contain financial and other covenants as well as cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements and believes the likelihood of noncompliance is remote. Refer to Note 6, Long term Debt and Credit Facilities, on the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for further information about the Company’s long-term debt and credit facilities.
In the first quarter of 2020, the Company increased the quarterly common stock dividend to $0.44 per share from $0.43 per share previously, effective in the second quarter of 2020.
Cash and cash equivalents increased $106 during the first nine months of 2020 to $989 at September 30, 2020, compared to $883 at December 31, 2019, most of which ($919 and $798, respectively) were held by the Company’s foreign subsidiaries.
During the nine months ended September 30, 2020, COVID-19 did not have a significant impact on the Company’s liquidity for its continued operating and cash needs. For more information regarding the anticipated impact of COVID-19, see “Executive Overview” and “Risk Factors” in Part II, Item 1A of this Quarterly Report and in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
For additional information regarding liquidity and capital resources, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
52

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Goodwill and Indefinite-Lived Intangible Assets
As previously disclosed, as a result of the COVID-19 pandemic, in the first quarter of 2020, the Company determined that a “triggering event” had occurred relative to its recently acquired Filorga skin health business and, as required, performed a quantitative analysis, with the assistance of a third-party valuation firm, of the value of the Filorga reporting unit and its indefinite-life intangible assets. Based on the analysis, the Company determined that the fair value of the Filorga reporting unit and the related indefinite life intangible assets were not impaired.
As of March 31, 2020, the fair value of the Filorga reporting unit exceeded its carrying value by 10%. While Filorga’s performance in the second and third quarters of 2020 was in line with its revised business plan, given the inherent uncertainties in estimating the future impacts of the COVID-19 pandemic on global macroeconomic conditions and on the Filorga business in particular, actual results may differ from management’s current estimates and could have an adverse impact on one or more of the assumptions used in our quantitative models related to the Filorga reporting unit, resulting in potential impairment charges in subsequent periods. A reduction in the long-term growth rate of 50 basis points or an increase in the discount rate of 25 basis points would result in a reduction of the fair value of the Filorga reporting unit of approximately 5%. Given the recent acquisition of Filorga, where there is inherently a lower surplus of fair value over carrying value, management will continue to assess triggering events that may necessitate additional qualitative or quantitative analyses of our reporting units and indefinite-lived intangible assets in future periods.
53

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Market Share Information
Management uses market share information as a key indicator to monitor business health and performance. References to market share in this Quarterly Report on Form 10-Q are based on a combination of consumption and market share data provided by third-party vendors, primarily Nielsen, and internal estimates. All market share references represent the percentage of the dollar value of sales of our products, relative to all product sales in the category in the countries in which the Company competes and purchases data (excluding Venezuela from all periods).
Market share data is subject to limitations on the availability of up-to-date information. In particular, market share data is currently not generally available for certain retail channels, such as eCommerce and certain club retailers and discounters. The Company measures year-to-date market shares from January 1 of the relevant year through the most recent period for which market share data is available, which typically reflects a lag time of one or two months. The Company believes that the third-party vendors it uses to provide data are reliable, but it has not verified the accuracy or completeness of the data or any assumptions underlying the data. In certain limited circumstances, the COVID-19 pandemic has impacted the ability of our third-party vendors to provide the Company with reliable updated market share data. In addition, market share information reported by the Company may be different from market share information reported by other companies due to differences in category definitions, the use of data from different countries, internal estimates and other factors.
Cautionary Statement on Forward-Looking Statements
This Quarterly Report on Form 10-Q may contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations and releases that set forth anticipated results based on management’s current plans and assumptions. Such statements may relate, for example, to sales or volume growth, net selling price increases, organic sales growth, profit or profit margin growth, earnings per share levels, financial goals, the impact of foreign exchange, the impact of COVID-19, cost-reduction plans, tax rates, new product introductions, commercial investment levels, acquisitions, divestitures, share repurchases, or legal or tax proceedings, among other matters. These statements are made on the basis of the Company’s views and assumptions as of this time and the Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Moreover, the Company does not nor does any other person assume responsibility for the accuracy and completeness of those statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Actual events or results may differ materially because of factors that affect international businesses and global economic conditions, as well as matters specific to the Company and the markets it serves, including the uncertain economic and political environment in different countries and its effect on consumer spending habits, foreign currency rate fluctuations, exchange controls, tariffs, price or profit controls, labor relations, changes in foreign or domestic laws, or regulations or their interpretation, political and fiscal developments, including changes in trade, tax and immigration policies, increased competition and evolving competitive practices (including from the growth of eCommerce and the entry of new competitors and business models), the ability to operate and respond effectively during a pandemic, epidemic or widespread public health concern, including COVID-19, disruptions in global supply chain, the availability and cost of raw and packaging materials, the ability to maintain or increase selling prices as needed, changes in the policies of retail trade customers, the emergence of new sales channels, the growth of eCommerce and the changing retail landscape (as consumers increasingly shop online), the ability to develop innovative new products, the ability to continue lowering costs and operate in an agile manner, the ability to maintain the security of our information technology systems from a cyber-security incident or data breach, the ability to achieve our sustainability goals, the ability to complete acquisitions and divestitures as planned, the ability to successfully integrate acquired businesses, the ability to attract and retain key employees, and the uncertainty of the outcome of legal proceedings, whether or not the Company believes they have merit. For information about these and other factors that could impact the Company’s business and cause actual results to differ materially from forward-looking statements, refer to the Company’s filings with the SEC (including, but not limited to, the information set forth under the captions “Risk Factors” and “Cautionary Statement on Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent Quarterly Reports on Form 10-Q).
54

COLGATE-PALMOLIVE COMPANY
Management’s Discussion and Analysis of Financial
Condition and Results of Operations
(Dollars in Millions Except Per Share Amounts)
Quantitative and Qualitative Disclosures about Market Risk
There is no material change in the information reported under Part II, Item 7, “Managing Foreign Currency, Interest Rate, Commodity Price and Credit Risk Exposure” contained in our Annual Report on Form 10-K for the year ended December 31, 2019.
55

COLGATE-PALMOLIVE COMPANY
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s management, under the supervision and with the participation of the Company’s Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of September 30, 2020 (the “Evaluation”). Based upon the Evaluation, the Company’s Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) are effective.
Changes in Internal Control Over Financial Reporting
The Company is in the process of upgrading its enterprise IT system to SAP S/4 HANA. This change has not had and is not expected to have a material impact on the Company’s internal controls over financial reporting.
Except as noted above, there were no changes in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
56

COLGATE-PALMOLIVE COMPANY
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
For information regarding legal matters, please refer to Note 11, Contingencies to the Condensed Consolidated Financial Statements contained in Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Item 1A. Risk Factors
With the exception of the additional risk factor relating to COVID-19 included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, which is reproduced below, there have been no material changes from the risk factors disclosed in Part 1, Item 1A. Risk Factors of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
We face various risks related to pandemics, epidemics or similar widespread public health concerns, which may have a material adverse effect on our business, results of operations, cash flows and financial condition.
We face various risks related to pandemics, epidemics or similar widespread public health concerns, including the novel coronavirus pandemic (“COVID-19”). A pandemic, epidemic or similar widespread health concern could have, and COVID-19 has had and may continue to have, a variety of impacts on our business, results of operations, cash flows and financial condition, including:
•Our ability to continue to maintain and support the health and safety of our employees, including key employees;
•Volatility in the demand for and availability of our products, which may be caused by the temporary inability of our consumers to purchase our products due to illness, financial hardship, quarantine, government actions mandating the closure of our distributors or retailers or imposing travel or movement restrictions, shifts in demand away from more discretionary or higher priced products to lower priced products, or pantry-loading activity;
•Changes in purchasing patterns of our consumers, including the frequency of visits by consumers to retail locations and a shift to purchasing our products online from eCommerce retailers;
•Inability to meet our customers’ needs and achieve our cost targets due to temporary or long-term disruptions in the manufacture, sourcing and distribution of our products or materials despite our business continuity and contingency plans in place for key manufacturing sites and the supply of raw and packaging materials;
•Failure of third parties on which we rely, including our suppliers, contract manufacturers, customers, commercial banks, joint venture partners and external business partners, to meet their obligations to us, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties;
•Significant changes in the economic and political conditions of the markets in which we operate, which could restrict and have restricted our employees’ ability to work and travel, could mandate and have mandated or caused the closure of certain distributors or retailers, our offices, shared business service centers and/or operating and manufacturing facilities or otherwise could prevent and have prevented us as well as our third-party partners, suppliers or customers from sufficiently staffing operations, including operations necessary for the manufacture, distribution, sale and support of our products; and/or
•Disruptions and volatility in the global capital markets, which may increase the cost of capital and adversely impact our access to capital, and currency and commodity prices.
Despite our efforts to manage these impacts, their ultimate impact also depends on factors beyond our knowledge or control, including the duration, severity and geographic scope of an outbreak, including COVID-19, and the actions taken to contain its spread and mitigate its public health and economic effects.
57

COLGATE-PALMOLIVE COMPANY
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On June 18, 2018, the Board authorized the repurchase of shares of the Company’s common stock having an aggregate purchase price of up to $5 billion under a new share repurchase program (the “2018 Program”), which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company’s compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company’s discretion, subject to market conditions, customary blackout periods and other factors.
The following table shows the stock repurchase activity for the three months in the quarter ended September 30, 2020:

Month |  | Total Number of Shares Purchased(1) |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) |  | Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs(3) (in millions)
July 1 through 31, 2020 |  | 27,155 |  |  | $ | 73.68 |  |  | — |  |  | $ | 3,074 |
August 1 through 31, 2020 |  | 1,822,418 |  |  | $ | 77.56 |  |  | 1,795,000 |  |  | $ | 2,934 |
September 1 through 30, 2020 |  | 2,968,503 |  |  | $ | 76.78 |  |  | 2,888,380 |  |  | $ | 2,713 |
Total |  | 4,818,076 |  |  | $ | 77.06 |  |  | 4,683,380 |  |  |

(1) Includes share repurchases under the 2018 Program and those associated with certain employee elections under the Company’s compensation and benefit programs
(2)The difference between the total number of shares purchased and the total number of shares purchased as part of publicly
announced plans or programs is 134,696 shares, which represents shares deemed surrendered to the Company to satisfy
certain employee elections under the Company’s compensation and benefit programs.
(3) Includes approximate dollar value of shares that were available to be purchased under the publicly announced plans or programs that were in effect as of September 30, 2020.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not Applicable.
Item 5. Other Information
None.
58

COLGATE-PALMOLIVE COMPANY
Item 6. Exhibits

Exhibit No. |  | Description
10-A |  | 364-day Credit Agreement, dated as of August 21, 2020, among Colgate-Palmolive Company, as Borrower, Citibank, N.A., as Administrative Agent and Arranger, and the Lenders party thereto.*
31-A |  | Certificate of the Chairman of the Board, President and Chief Executive Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.*
31-B |  | Certificate of the Chief Financial Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.*
32 |  | Certificate of the Chairman of the Board, President and Chief Executive Officer and the Chief Financial Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. § 1350.**
101 |  | The following materials from Colgate-Palmolive Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020, formatted in Inline eXtensible Business Reporting Language (Inline XBRL): (i) the Condensed Consolidated Statements of Income; (ii) the Condensed Consolidated Statements of Comprehensive Income; (iii) the Condensed Consolidated Balance Sheets; (iv) the Condensed Consolidated Statements of Cash Flows; (v) Condensed Consolidated Statements of Changes in Shareholders’ Equity and (vi) Notes to Condensed Consolidated Financial Statements.
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*

__________
* Filed herewith.
** Furnished herewith.
59

COLGATE-PALMOLIVE COMPANY
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| COLGATE-PALMOLIVE COMPANY
| (Registrant)
| Principal Executive Officer:
October 30, 2020 | /s/ Noel R. Wallace
| Noel R. Wallace
| Chairman of the Board, President and Chief Executive Officer
| Principal Financial Officer:
October 30, 2020 | /s/ Henning I. Jakobsen
| Henning I. Jakobsen
| Chief Financial Officer
| Principal Accounting Officer:
October 30, 2020 | /s/ Philip G. Shotts
| Philip G. Shotts
| Vice President and Controller

60